Pulmonary delivery of RNA
Pulmonary delivery of circular RNA via lipid nanoparticles effectively targets lung tissues to restore CFTR function, overcoming delivery challenges and immune responses, achieving durable therapeutic efficacy in cystic fibrosis treatment.
Patent Information
- Application Number
- PCT/US2026/026678
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-05
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
Current therapies for cystic fibrosis, such as CFTR modulators and airway clearance techniques, are limited in effectiveness due to drug resistance, individual variability, and the challenge of delivering drugs to thick, mucus-obstructed lungs, with gene or protein-based therapies risking immune responses and adverse side effects.
Pulmonary delivery of circular RNA using lipid nanoparticles (LNPs) designed to target lung tissues, incorporating ionizable lipids and pulmonary surfactants, to express CFTR and restore chloride transport function without triggering immune reactions.
The LNP-circRNA approach achieves sustained chloride response lasting up to two weeks, restoring approximately 10% of normal chloride efflux and functional correction of CFTR in lung epithelium, addressing the limitations of existing treatments.
Smart Images

Figure IMGF000010_0001 
Figure IMGF000021_0001_TABLE 
Figure IMGF000029_0001_TABLE
Abstract
Description
Docket No. UM-44842.601PULMONARY DELIVERY OF RNAThe present application claims priority to United States Provisional Patent Application Serial Number 63 / 800,096, filed May 5, 2025, the disclosure of which is herein incorporated by reference in its entirety.TECHNICAL FIELD
[0001] The present technology provides compositions and methods for pulmonary deliver}' of RNA. For example, embodiments of the technology provides pulmonary deliver}' of circular RNA for the treatment of pulmonary diseases such as cystic fibrosis.BACKGROUND
[0002] Cystic fibrosis (CF) is a life-threatening autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, primarily affecting the lungs and digestive system. These mutations lead to the buildup of thick, sticky mucus that clogs airways, promotes infections, and causes progressive respiratory decline, with symptoms often developing in early childhood. While current therapies, such as CFTR modulators and airway clearance techniques, have helped improve uality of life and life expectancy, managing this disease remains complex and burdensome. Additionally, many treatments focus on symptom relief rather than addressing the underlying genetic defect. Moreover, therapies that directly target CFTR function often show variable effectiveness depending on the specific mutation a patient carries, leaving some individuals with limited or no therapeutic options. Further complicating treatment is the challenge of delivering drugs effectively to affected tissues, particularly the thick, mucus-obstructed lungs. Drug resistance and individual variability in therapeutic response also hinder consistent, long-term success. Additionally, current gene or protein-based therapies risk triggering immune responses, which can diminish effectiveness or lead to adverse side effects. These challenges highlight the urgent need for precise, mutation-specific treatments that directly address the root cause of CF while being minimally invasive, well-tolerated, and less likely to provoke an immune reaction. SUMMARY
[0003] The present technology provides compositions and methods for pulmonary deliver}' of RNA. For example, embodiments of the technology provide pulmonary delivery of circular RNA for the treatment of pulmonary diseases such as cystic fibrosis.Docket No. UM-44842.601
[0004] In some embodiments, the technology provides compositions and methods for delivery of RNA (e.g., circular RNA encoding a molecule of interest) to lungs and lung tissues (e.g., respiratory mucosa, bronchial epithelial cells, lung ciliated cells, ionocytes) to express a molecule of interest (e.g., a factor that treats or prevents or otherwise ameliorates a pulmonary disease or condition) without causing undue adverse immune responses. In some embodiments, this is achieved through the use of lipid nanoparticles designed to effectively deliver RNA to the desired target tissues and regions. In some embodiments, where circular RNA is utilized, the circular RNA comprises an internal ribosome entry site (IRES). In some embodiments, the circular RNA comprises a Kozak Sequence.
[0005] In some embodiments, the circular RNA encoding the molecule of interest (e.g., CFTR) comprises a codon-optimized coding sequence. In some embodiments, the codon-optimized coding sequence is optimized for expression in human cells. In some embodiments, the IRES comprises a Coxsackievirus B3 (CVB3) IRES.
[0006] In some embodiments, the lipid nanoparticle comprises an ionizable lipid. In some embodiments, the ionizable lipid comprises an ionizable cationic lipid. In some embodiments, the cationic lipid is a lipid capable of being positively charged, e.g., under physiological conditions. In some embodiments, the ionizable lipid comprises a synthetic amino lipid. In some embodiments, the ionizable lipid comprises SMI 02. In some embodiments, the lipid nanoparticle comprises a pulmonary surfactant (PS) (e.g., coating or mixture). In some embodiments, the PS comprises about 10% to 30% (w / w) (e.g., 20%) of the total surfactant content. In some embodiments, the lipid nanoparticle size ranges from 10 nm to 1000 nm (e.g., 50 nm to 150 nm), although other size may be used. In some embodiments, the lipid nanoparticles have a poly dispersity7index (PDI) from 0.05 to 0.3, although other ranges may¬ be used.
[0007] Further provided herein are compositions and methods for the treatment of pulmonary diseases and conditions by delivering one or more factors to target tissues and regions of interest. For example, provided herein are compositions and methods for delivering functional cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis. In some embodiments, the lipid nanoparticle comprises an RNA (e.g.. a circular RNA) encoding a functional cystic fibrosis transmembrane conductance regulator (CFTR). In some embodiments, the RNA encodes a wild-ty pe CFTR or a functional fragment thereof. In some embodiments, the RNA lacks one or more CFTR non-coding sequences (e.g., consists of only CFTR coding sequence).Docket No. UM-44842.601
[0008] Also provided herein are uses of any of the compositions. For example, provided herein are uses of the compositions (e.g., lipid nanoparticle containing an RNA cargo) for the treatment or prevention of a pulmonary disease or condition (e.g., cystic fibrosis (CF)).
[0009] Further provided herein are kits comprising any of the compositions. The kits may further comprise one or more other biological agents, packaging, delivery devices (e.g., a nebulizer, a dry powder inhaler, a metered-dose inhaler, a metered dose spray pump, a soft mist inhaler or a inhalation therapy device), and / or instructions for use with a subject (e.g., a human patient).
[0010] Also provided herein are methods of treating a subject comprising administering any of the compositions to a subject. For example, in some embodiments, the methods comprise administering an lipid nanoparticle comprising an RNA encoding a therapeutic agent to lung tissues (e.g., respiratory mucosa, bronchial epithelial cells, lung ciliated cells, ionocytes). For example, in some embodiments, the methods comprise administering a lipid nanoparticle comprising an RNA encoding a functional CFTR to a lung of a subject under conditions such that signs or symptoms of cystic fibrosis disease are reduced. In some embodiments, the administering results in restoration of physiological function of CFTR to transport Cl- across cell membranes of bronchial epithelial cells.
[0011] Further provided herein are methods of manufacturing nanoparticles. In some embodiments, the methods comprise encapsulating (e.g., by mixing (e.g., microfluidic mixing)) a cargo molecule (e.g.. circular RNA (e.g., encoding a functional CFTR)) to form a lipid nanoparticle suitable for delivery to target cells.
[0012] In some embodiments, the method of manufacturing comprises a two-step process: (1) encapsulating the cargo molecule in a lipid nanoparticle by microfluidic rapid mixing at an N:P ratio of about 6:1, wherein the lipid phase comprises ionizable lipid, helper lipid (e.g., DSPC), PEG-lipid (e.g., DMG-PEG2000), and cholesterol at a molar ratio of about 50:10:1.5:38.5, followed by dialysis purification; and (2) coating the purified lipid nanoparticle with a pulmonary' surfactant (e.g., poractant alfa) by mixing for about 5 minutes and incubating for about 30 minutes. In some embodiments, the lipid nanoparticle formulation further comprises a cryoprotectant (e.g., about 10% sucrose in PBS).DEFINITIONS
[0013] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In case of conflict, the present document, including definitions, will control. Preferred methods and materials areDocket No. UM-44842.601described below, although methods and materials similar or equivalent to those described herein can be used in practice or testing of the present disclosure. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and not intended to be limiting.
[0014] The terms “comprise(s),’' “include(s),” “having,” “has,” “can,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that do not preclude the possibility of additional acts or structures. The singular forms “a,” “an” and “the” include plural references unless the context clearly dictates otherwise. The present disclosure also contemplates other embodiments “comprising,” “consisting of’ and “consisting essentially of,” the embodiments or elements presented herein, whether explicitly set forth or not.
[0015] For the recitation of numeric ranges herein, each intervening number there between with the same degree of precision is explicitly contemplated. For example, for the range of 6-9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the number 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.
[0016] The term “administration” refers to the act of giving a drug, prodrug, or other agent, or therapeutic treatment (e.g., pharmaceutical compositions of the present disclosure) to a subject or in vivo, in vitro, or ex vivo cells, tissues, and organs. Exemplary routes of administration to the human body can be through the mouth (oral), nose (nasal), lungs (e.g., inhalant, intratracheal), skin (transdermal), oral mucosa (buccal), by injection (e.g., intravenously, subcutaneously, intratumorally, intraperitoneally, etc.) and the like.
[0017] The term “protein” is used synonymously with “peptide,” “polypeptide,” or “peptide fragment.” A “purified” polypeptide, protein, peptide, or peptide fragment is substantially free of cellular material or other contaminating proteins from the cell, tissue, or cell-free source from which the amino acid sequence is obtained, or substantially free from chemical precursors or other chemicals when chemically synthesized.
[0018] The terms “treat,” “treatment,” and “treating” refer to reducing the amount or severity of a particular condition, disease state, or symptoms thereof, in a subject presently experiencing or afflicted with the condition or disease state. The terms do not necessarily indicate complete treatment (e.g., total elimination of the condition, disease, or symptoms thereof). "Treatment,” encompasses any administration or application of a therapeutic or technique for a disease (e.g., in a mammal, including a human), and includes inhibiting the disease, arresting itsDocket No. UM-44842.601development, relieving the disease, causing regression, or restoring or repairing a lost, missing, or defective function; or stimulating an inefficient process.
[0019] The terms “prevent,” “prevention,” and preventing” refer to reducing the likelihood of a particular condition or disease state from occurring in a subject not presently experiencing or afflicted with the condition or disease state. The terms do not necessarily indicate complete or absolute prevention.
[0020] The term "pharmaceutical composition" as used herein means a product comprising an active, compound or a salt thereof together with pharmaceutical excipients such as buffer, presen alive and tonicity modifier, said pharmaceutical composition being useful for treating, preventing or reducing the severity of a disease or disorder by administration of said pharmaceutical composition to a person. Thus a pharmaceutical composition is also known in the art as a pharmaceutical formulation.
[0021] The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredients, its use in the therapeutic compositions is contemplated. Supplementary active ingredients, such as antibiotics, antifungals, antimicrobials, can also be incorporated into the compositions. In addition, various adjuvants such as are commonly used in the art may be included. These and other such compounds are described in the literature, e.g., in the Merck Index, Merck & Company, Rahway, N.J. Considerations for the inclusion of various components in pharmaceutical compositions are described, e.g., in Gilman et al. (Eds.) (2006); Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 11th Ed., The McGraw-Hill Companies.
[0022] The term “subject” as used herein refers to any animal, including but not limited to, human and non-human animals (e.g., dogs, cats, cows, horses, sheep, mice, rats, etc.). As used herein, the term “patient” typically refers to a human subject that is being treated for a disease or condition or prophylactically.
[0023] The term “therapeutically effective amount” refers to the amount of a composition of the present invention that is capable of achieving a therapeutic effect in a subject in need thereof. For example, a therapeutically effective amount of a composition of the present invention can be the amount that is capable of preventing or relieving one or more symptoms associated with a disease or disorder.Docket No. UM-44842.601
[0024] Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. For example, any nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry7and hybridization described herein are those that are well known and commonly used in the art. The meaning and scope of the terms should be clear; in the event, however of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.BRIEF DESCRIPTION OF THE DRAWINGS
[0025] The patent or application file contains drawings executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary7fee.
[0026] Having thus described the presently disclosed subject matter in general terms, reference will now be made to the accompanying Figures, which are not necessarily drawn to scale, and wherein:
[0027] FIG. 1 shows a schematic illustration of Circular RNA cystic fibrosis transmembrane conductance regulator (circRNA-CFTR) pulmonary delivery using lipid nanoparticles (LNPs) for long-lasting Cystic Fibrosis (CF) therapy.
[0028] FIG. 2 shows the circRNA design, synthesis, and characterization. (A) Structure of CFTR-plasmid. (B) DNA Gel electrophoresis validates the restriction digestion of the CFTR plasmid by BspQI. (C) RNA Gel electrophoresis validating circRNA synthesis.
[0029] FIG. 3 shows a Design of Experiment (DOE) study for the optimization of LNP for pulmonary delivery of circRNA. (A, B) bioluminescence of CF cells treated with a series of LNPs loaded with circRNA-firefly luciferase (fLuc). (C) IVIS images (left) and quantified bioluminescence signal (right) in the region of interest (ROI) in BALB / c mouse lungs (marked in the images), at a series of time point post intratracheal administration.
[0030] FIG. 4 shows CFTR expression kinetics and cellular physiology in CF cells. (A) Flow cytometry was performed to measure the CFTR+in cells. (B) CFTR protein expression was determined by western blot (WB). (C) Confocal microscopy revealed restored CFTR localization to the plasma membrane stained by the anti-CFTR antibody. (D) Using chamber analysis showed chloride efflux function. FSK: forskolin, activator of CFTR channel function. GlyHlOl: CFTR inhibitor.Docket No. UM-44842.601
[0031] FIG. 5 shows the evaluation of the CF therapeutic efficacy of LNP-circRNA-CFTR in a CF mouse model. Shown are fluorescence microscopy images of immunofluorescence staining was performed to measure CFTR expression in lung (A) Alveolar epithelial cells, (B) Goblet cell, (C) Ciliated cell and (D) Club cell.
[0032] FIG. 6 shows the evaluation of lung ventilation function by 4D-CT imaging in Cftr-S489X CF mice. (A) Schematic illustration of 4D-CT of mice for assessing the lung respiratory function. (B) Study timeline of 4D-CT imaging of CF mice treated with circRNA-CFTR-psLNPs or controls. (C) Functional lung metrics determined by 4D-CT imaging analysis. (D) Representative coronal XV ventilation maps shown across respiratory phases.
[0033] FIG. 7 shows single-dose intranasal circRNA-CFTR-psLNPs resulted in efficient and durable CFTR functional restoration in CF rabbit nostrils. (A) Representative NPD real-time tracing curves of untreated wild-type and F508del rabbits treated with vehicle buffer, benchmark ETI, or intranasal instillation of circRNA-CFTR-psLNPs, showing NPD changes in response to CFTR agonist FSK and CFTR inhibitors for up to 7 days post treatment. (B) Quantitated NPD voltage changes in response to FSK (mV) over time. Red dashed line indicates the clinically significant therapeutic threshold defined at 10% mV between wild-type rabbits and untreated F508del rabbits.
[0034] FIG. 8 shows psLNP delivery of mRNA-Cre to ferret airway epithelial cells. (A, B) Tissue staining images from differentiated ferret bronchial epithelia ALI culture generated from Cre / Loxp reporter ROSA-TG ferrets, showing Cre-mediated GFP conversion and colocalization with epithelial cell subty pe biomarkers including FOXJ1 (ciliated cells) and TP63 (basal progenitor cells).
[0035] FIG.9 shows cell-type specificity of pulmonary psLNP delivery in Ail 4 reporter mice. (A) 3D imaging of optically-cleared lung tissue demonstrating efficient delivery of intratracheally instilled mRNA-Cre-psLNPs to lung epithelia. (B) Flow cytometry results showing that, relative to LNPs, psLNPs promoted mRNA-Cre delivery to lung / tracheal epithelial cells, as well as alveolar macrophages and dendritic cells, but not neutrophils or T / B cells.
[0036] FIG. 10 shows intratracheal instillation of circRNA-CFTR-psLNPs in Cftr-S489X CF mice resulted in efficient and durable CFTR expression in multiple subsets of CF-relevant airway epithelial cells. (A, B) Western blot image and densitometric quantification of CFTR expression levels relative to actin in the lung. (C) Fluorescence microscopy images of lung tissues stained for CFTR and representative CF-affected airway epithelial cell markers, including Tubulin (ciliated cells), Muc5AC (goblet cells), and SCGB1A1 (club cells).Docket No. UM-44842.601
[0037] FIG. 11 shows QCM-D characterization of psLNP interaction with mucus and pulmonary surfactant models. (A) QCM-D resonance frequency (F) and dissipation (D) kinetics during the three phases of addition, incubation, and rinsing of psLNPs with an artificial mucus model on the gold substrate, with LNPs serving as a control. (B, C) Change in frequency (delta-F) and change in dissipation (delta-D) for the 7th harmonic relative to baseline mucus, showing that PS coating on psLNPs enhanced psLNP interaction with mucus under CF-mimicking buffer conditions (pH 5.6, ionic strength 154 mM).
[0038] FIG. 12 shows mucus penetration and RNA delivery by psLNPs in ALI-cultured CF cells. (A) Schematic illustration of Cy5-circRNA-CFTR-psLNP or Cy5-circRNA-CFTR-LNP transfection to ALI 16HBE-ge-G55 ID cells that generated mucus after 21 days of ALI culture. (B) Confocal fluorescence microscopy Z-stack images showing the distribution of Cy5-circRNA across a 300-micrometer cross-section in the interface of ALI cells and mucus at 0.5 and 2 hours after treatment. (C) ImageJ densitometric quantification of fluorescence signal. (D) Flow cytometric analysis showing EGFP-positive cells 24 hours after mRNA-EGFP transfection by LNPs or psLNPs.
[0039] FIG. 13 shows protein corona remodeling and oxidative stress reduction by psLNPs. (A) Heatmap of Z-score-normalized abundances of the top differential proteins between LNP circRNA-CFTR and psLNP circRNA-CFTR protein coronas. (B) Schematic illustration and results of in vitro oxidative stress assay in MH-S cells treated with LNPs or psLNPs with BALF corona, showing that psLNP protein coronas attenuated oxidative stress. (C) Schematic illustration and results of in vivo oxidative stress analysis in C57BL / 6 mice administered LNP circRNA-CFTR and psLNP circRNA-CFTR intratracheally.
[0040] FIG. 14 shows circRNA-CFTR biostability and thermostability compared to mlpsi-mRNA-CFTR. (A, B) Agarose gel electrophoresis images and ImageJ densitometric quantification showing the fractions of intact circRNA-CFTR and mlpsi-mRNA-CFTR after storage in sucrose-supplemented PBS at -20 degrees C for up to 7 days. (C, D) Agarose gel electrophoresis images and ImageJ densitometric quantification of the fraction of intact circRNA-CFTR and mlpsi-mRNA-CFTR after incubation in diluted FBS at 37 degrees C for 30 minutes.DETAILED DESCRIPTION
[0041] The present disclosure relates to compositions and methods for pulmonary deliver}' of RNA. For example, embodiments of the technology provides pulmonary delivery of circular RNA for the treatment of pulmonary diseases such as cystic fibrosis.Docket No. UM-44842.601
[0042] Cystic fibrosis (CF) is a life-threatening autosomal recessive disease with > 30,000 annual new cases in all races and ethnicities [6, 7] in the US [1], Loss-of-function mutations in CFTR lead to impaired chloride channel function, resulting in thick mucus buildup, electrolyte imbalances, and organ dysfunction in multiple organs [2-4], Among >300 disease causing mutations, CFTR-F508del is the most dominant one. In the lung, defective CFTR causes thick and sticky mucus obstructing the airway, leading to serious lung infections [5], The current standard of care treatment for CF is small molecular CFTR modulators that only partially restore the Cl" transport function of CFTR, and patients often need to take these medicines daily, w ith limited patient compliance. Further, these drugs are limited to treat CF patients with specific subtypes of CFTR mutations and are ineffective for patients of CFTR null mutations. This demands innovation in CF therapeutic approaches.
[0043] Gene therapy holds the potential to treat CF irrespective of patient CFTR mutation profiles. rnRNA has garnered significant attention for gene therapy because of their generally good safety and promising therapeutic efficacy. rnRNA offers amplified production of therapeutic proteins through rapid, repeated translation in dividing and non-dividing cells. rnRNA is eventually degradable without genomic integration or metabolite toxicity. However, the current modified rnRNA still has limited stability, [14, 15] which requires the use of cold chains and leads to short duration of protein translation. Further, their limited stability' may cause strong inflammation and inhibit protein translation by PKR activation
[0016] , Though self-amplifying rnRNA (saRNA) sustains protein production.
[0017] the encoded RNA replicon in saRNA is sensitive to RNA engineering, interacts with host factors, and may elicit anti-replicon immunity' [18, 19] that can prevent repeated dosing, which is critical for long-term effective CF therapy. One recent Phase I / II clinical trial (ClinicalTrials.gov ID NCT03375047) showed the overall promising safety of an inhaled rnRNA drug MRT5005 in 42 CF patients, yet without significant CF therapeutic efficacy
[0011] ,
[0044] The present technology overcomes the limitations and failures of prior methodologies through the use of, for example, stable RNA molecules and delivery' systems (e.g., LNPs) designed to provide therapeutic delivery of RNAs to clinically relevant locations. In some embodiments, circular RNA (circRNA) is employed. circRNA is highly stable and can efficiently and durably produces genuine protein therapeutics in vivo with minimal immune toxicity'. It is contemplated that circRNA alleviate overly strong inflammation or global RNA degradation due to its high stability and hence slow production of immunogenic nucleotides and oligonucleotides. Experiments conducted during the development of embodiments of the present technology showed that all treated animal models, from multiple species (e.g., miceDocketNo. UM-44842.601and rabbits) exhibited a sustained chloride response lasting for two weeks following exposure to LNP-circRNA-CFTR. Compared to LNP-mRNA-CFTR, this approach demonstrated improved CFTR production, prolonged protein expression duration, and enhanced functional restoration of chloride transport.
[0045] LNPs were developed with enhanced pulmonary deliver}7of therapeutic RNA. Ionizable LNPs were tested with different ionizable lipids. A design of experiment (DOE) approach was utilized to systematically screen and identify optimal formulations. Based on the results of the DOE analysis, successful formulations were selected for further evaluation. Implementing a DOE and desi rabi 1 i ty index framework allowed simultaneous assessment of multiple variables, streamlining the optimization process while reducing the use of animal model.
[0046] The present invention demonstrates that RNA (e.g., circRNA) delivered via these LNPs is translated to a protein product that successfully traffics to the plasma membrane in bronchial epithelial cells. Additionally, in vivo functional correction of CFTR in the tracheal epithelium of mice and rabbit model were further shown. These changes were evaluated in electrophysiology using the Ussing chamber. It has been estimated that restoring 10% of CFTR mRNA or 10%-35% of protein function would be sufficient to ameliorate disease [46, 47], The present disclosure indicates that exposure to LNP-circRNA-CFTR one time meets this benchmark, restoring approximately one second of normal chloride efflux with effects for at least 2 weeks.
[0047] In some embodiments, the LNP comprises an ionizable lipid. In some embodiments, the ionizable lipid comprises an ionizable cationic lipid. In some embodiments, the cationic lipid is a lipid capable of being positively charged, e.g., under physiological conditions. In some embodiments, the ionizable lipid comprises a synthetic amino lipid. The present disclosure is not limited to particular lipids for use in lipid nanoparticles.
[0048] In some embodiments, the ionizable lipid comprises 9-Heptadecanyl 8-{(2-hy droxyethyl)[6-oxo-6-(undecyloxy)hexyl] amino } octanoate (SM-102), 5-(dimethylamino)-pentanoic acid, (6Z)-l,2-di-(4Z)-4-decen-l-yl-6-dodecen-l-yl ester (CL1),(TCL053), bis((Z)-12-(((non-2-yn-l-yloxy)carbonyl)oxy)octadec-9-en-l-yl) 3,3’-((2- (diethylamino)ethyl)azanediyl)dipropionate (RCB4-8), 3-[4,4-Bis(octyloxy)-l-oxobutoxy]-2-Docket No. UM-44842.601[[[[3-(diethylamino)propoxy]carbonyl]oxy]methyl]propyl (9Z,12Z)-9,12-octadecadi enoate (LP-01), [(4-Hydroxybutyl)azanediyl]di(hexane-6,l-diyl) bis(2-hexyldecanoate) (ALC-0315), O-(Z,Z,Z,Z-heptatriaconta-6,9,26,29-tetraen-19-yl)-4-(N,N-dimethylamino) (DLIN-MC3-DMA), [(Z)-non-2-enyl] 8-[2-(dimethylamino)ethylsulfanylcarbonyl-[8-[(Z)-non-2-enoxy]-8-oxooctyl| amino] octanoate (ATX-002), Di((Z)-non-2-en-l-yl) 9-((4-dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 1,1 '-((2-(4-(2-((2-(Bis(2-hydroxydodecyl)amino)ethyl)(2 -hydroxy dodecyl) amino)ethyl)piperazin-l-yl)ethyl)azanediyl)bis(dodecan-2-ol) (Cl 2-200), or combinations thereof.
[0049] Such lipids are commercially available (e.g., from Broad Pharma, San Diego, CA or Sigma- Aldrich, St. Louis, MO). Additional lipids are described, for example, inTenchov et al., ACS Nano 2021, 15, 11, 16982-17015; herein incorporated by reference in its entirety.
[0050] In some embodiments, the LNP comprises a surfactant. In some embodiments, the surfactant comprises a pulmonary surfactant (PS). In some embodiments, the surfactant comprises one or more or all of dipalmitoylphosphatidylcholine (DPPC), phospholipids (e.g., phosphatidylcholine (PC), phosphatidylglycerol (PG)), surfactant proteins (e.g., SP-A, SP-B, SP-C and SP-D), and neutral lipids (Cholesterol). In some embodiments, the surfactant comprises Colfosceril palmitate (Exosurf) (a mixture of DPPC with hexadecanol and tyloxapol added as spreading agents), Pumactant (Artificial Lung Expanding Compound or ALEC) (a mixture of DPPC and PG), KL-4 (composed of DPPC, palmitoyl-oleoyl phosphatidylglycerol, and palmitic acid, combined with a 21 amino acid synthetic peptide that mimics the structural characteristics of SP-B), Venticute (DPPC, PG, palmitic acid and recombinant SP-C), or Lucinactant (DPPC, POPG, and palmitic acid). In some embodiments, the surfactant is an animal-derived surfactant (e.g., extracted from animal lung lavage fluid or minced animal lung and optionally combined with additional components such as DPPC, palmitic acid, and tripalmitin).
[0051] In some embodiments, the LNP comprises a saccharide. In some embodiments, the LNP comprises an oligosaccharide. In some embodiments, the LNP comprises alow molecular weight oligosaccharide. In some embodiments, the LNP comprises chitosan. In some embodiments, the LNP comprises an alginate oligosaccharide. In some embodiments, the LNP comprises oligo-G.
[0052] In some embodiments, LNPs are coated with a surfactant and / or saccharide. In some embodiments, the LNPs are coated 5% or more (e.g., 10%, 20%, 30%, 40%). In some embodiments, the LNPs are mixed with a surfactant and / or saccharide. In some embodiments, the LNPs are mixed at a ratio of 20: 1, 15:1, 10: 1, 5: 1, or 2: 1 (ionizable lipid: surfactant).Docket No. UM-44842.601
[0053] In some embodiments, the lipid nanoparticle is formed at an N:P ratio (nitrogen-to-phosphate ratio) of about 2:1 to about 10:1. In some embodiments, the N:P ratio is about 6:1. In some embodiments, the pulmonary surfactant comprises poractant alfa (Curosurf). In some embodiments, the lipid nanoparticle comprising a pulmonary surfactant coating is manufactured by a two-step process comprising: (1) synthesizing RNA-loaded lipid nanoparticles by microfluidic rapid mixing, followed by dialysis purification; and (2) coating the purified lipid nanoparticles with a pulmonary surfactant by mixing for about 5 minutes and further incubating for about 30 minutes.
[0054] In some embodiments, the average LNP diameter of the LNP formulation may be between 10s of nm and 100s of nm, e.g., measured by dynamic light scattering (DLS). In some embodiments, the average LNP diameter of the LNP formulation may be from about 40 nm to about 150 nm, such as about 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm. In some embodiments, the average LNP diameter of the LNP formulation ranges from about 1 nm to about 500 nm, from about 5 nm to about 200 nm, from about 10 nm to about 120 nm.
[0055] In some embodiments, the LNP is relatively homogenous. A poly dispersity index may be used to indicate the homogeneity' of an LNP, e.g., the particle size distribution of the lipid nanoparticles. A small (e.g., less than 0.3) polydispersity index generally indicates a narrow particle size distribution. An LNP may have a polydispersity’ index from about 0 to about 0.25, such as 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, or 0.25.
[0056] The efficiency of encapsulation of a cargo (e.g., an RNA (e.g., a circular RNA)), describes the amount of nucleic acid that is encapsulated or otherwise associated with an LNP after preparation, relative to the initial amount provided. The encapsulation efficiency is desirably high (e.g., close to 100%; e.g., greater than 90%; greater than 95%). The encapsulation efficiency may be measured, for example, by comparing the amount of nucleic acid in a solution containing the lipid nanoparticle before and after breaking up the lipid nanoparticle with one or more organic solvents or detergents. An anion exchange resin may be used to measure the amount of free nucleic acid (e.g., RNA) in a solution. Fluorescence may be used to measure the amount of free nucleic acid (e.g., RNA) in a solution. For the lipid nanoparticles described herein, the encapsulation efficiency of a nucleic acid may be at least 50%, for example 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. In some embodiments, the encapsulation efficiency mayDocket No. UM-44842.601be at least 80%. In some embodiments, the encapsulation efficiency may be at least 90%. In some embodiments, the encapsulation efficiency may be at least 95%.
[0057] In some embodiments, the lipid nanoparticle composition further comprises a cryoprotectant. In some embodiments, the cryoprotectant comprises sucrose. In some embodiments, the lipid nanoparticle composition comprises about 5% to about 15% (e.g., about 10%) sucrose in a pharmaceutically acceptable buffer (e.g., PBS). In some embodiments, the lipid nanoparticle composition is stable through at least about 6 freeze-thaw cycles (e.g., between about -80 degrees C and about room temperature) with minimal changes in nanoparticle size, polydispersity index, RNA encapsulation efficiency, or RNA expression efficiency.
[0058] Embodiments of the present disclosure provide a lipid nanoparticle comprising a circular RNA cargo (e.g., encoding a functional cystic fibrosis transmembrane conductance regulator (CFTR) or other factor of interest). Circular RNAs can be produced from linear RNAs in a number of ways. In one embodiment, circular RNAs are produced from a linear RNA by back splicing of a downstream 5' splice site (splice donor) to an upstream 3' splice site (splice acceptor). Circular RNAs can be generated in this manner by any suitable splicing method. For example, linear RNAs containing various types of introns, including self-splicing group I introns, self-splicing group II introns, spliceosomal introns, and tRNA introns can be circularized. In particular, group I and group II introns have the advantage that they can be readily used for production of circular RNAs in vitro as well as in vivo because of their ability to undergo self-splicing due to their autocatalytic ribozy me activity.
[0059] Alternatively, circular RNAs can be produced in vitro from a linear RNA by chemical or enzymatic ligation of the 5' and 3' ends of the RNA. Chemical ligation can be performed, for example, using cyanogen bromide (BrCN) or ethyl-3-(3'- dimethylaminopropyl) carbodiimide (EDC) for activation of a nucleotide phosphomonoester group to allow phosphodiester bond formation. See e.g., Sokolova (1988) FEBS Lett 232: 153-155; Dolinnaya et al. (1991) Nucleic Acids Res., 19:3067-3072; Fedorova (1996) Nucleosides Nucleotides Nucleic Acids 15:1137-1147; herein incorporated by reference. Alternatively, enzymatic ligation can be used to circularize RNA. Exemplary ligases that can be used include T4 DNA ligase (T4 Dnl), T4 RNA ligase 1 (T4 Rnl 1), and T4 RNA ligase 2 (T4 Rnl 2).
[0060] Additionally, splint ligation using an oligonucleotide splint that hybridizes with the two ends of a linear RNA can be used to bring the ends of the linear RNA together for ligation. Hybridization of the splint, which can be either a deoxyribooligonucleotide or a ribooligonucleotide, orientates the 5’-phophate and 3’-OH of the RNA ends for ligation.Docket No. UM-44842.601Subsequent ligation can be performed using either chemical or enzymatic techniques, as described above. Enzymatic ligation can be performed, for example, with T4 DNA ligase (DNA splint required), T4 RNA ligase 1 (RNA splint required) or T4 RNA ligase 2 (DNA or RNA splint). Chemical ligation, such as with BrCN or EDC, in some cases is more efficient than enzy matic ligation if the structure of the hybridized splint-RNA complex interferes with enzymatic activity. See, e.g., Dolinnaya et al. (1993) Nucleic Acids Res 21(23):5403-5407; Petkovic et al. (2015) Nucleic Acids Res 43(4):2454-2465; herein incorporated by reference in their entireties.
[0061] Additional methods for circularizing RNA are described, for example, in Obi et al., Methods. 2021 Mar 2; 196: 85— 103; herein incorporated by reference in its entirety. A circular RNA may further comprise an internal ribosome entry site (IRES) operably linked to an circRNA sequence to facilitate translation initiation. Inclusion of an IRES permits the translation of one or more open reading frames from a circular RNA. The IRES element attracts a eukary otic ribosomal translation initiation complex and promotes translation initiation. See, e.g., Kaufman et al., Nuc. Acids Res. (1991) 19:4485-4490; Gurtu et al., Biochem. Biophys. Res. Comm. (1996) 229:295-298; Rees et al.. BioTechniques (1996) 20:102-110; Kobayashi et al., BioTechniques (1996) 21:399-402; and Mosser et al., BioTechniques 199722 150-161).
[0062] A multitude of IRES sequences are available and include sequences derived from a wide variety of viruses, such as from leader sequences of picomaviruses such as the encephalomyocarditis virus (EMCV) UTR (Jang et al. J. Virol. (1989) 63: 1651-1660). the polio leader sequence, the hepatitis A virus leader, the hepatitis C virus IRES, human rhinovirus type 2 IRES (Dobnkova et al., Proc. Natl. Acad. Sci. (2003) 100(25): 15125-15130), an IRES element from the foot and mouth disease virus (Ramesh et al., Nucl. Acid Res. (1996) 24:2697-2700), a giardiavirus IRES (Garlapati et al., J. Biol. Chem. (2004) 279(5):3389-3397), and the like. A variety of nonviral IRES sequences will also find use herein, including, but not limited to IRES sequences from yeast, as well as the human angiotensin II type 1 receptor IRES (Martin et al., Mol. Cell Endocrinol. (2003) 212:51-61), fibroblast grow th factor IRESs (FGF-1 IRES and FGF-2 IRES, Martineau et al. (2004) Mol. Cell. Biol. 24(17):7622-7635), vascular endothelial growth factor IRES (Baranick et al. (2008) Proc. Natl. Acad. Sci. U.S.A.105(12):4733-4738, Stein et al. (1998) Mol. Cell. Biol. 18(6):3112-3119, Bert et al. (2006) RNA 12(6): 1074-1083), and insulin-like growth factor 2 IRES (Pedersen et al. (2002) Biochem. J. 363(Pt 1): 37-44).
[0063] In some embodiments, the IRES comprises a Coxsackievirus B3 (CVB3) IRES. CVB3 IRES has been shown to drive efficient protein translation from circRNA constructs.DocketNo. UM-44842.601
[0064] Kozak sequences enhance translation initiation in circRNA constructs. In some embodiments, including a Kozak consensus sequence (e.g.. ACCAUGG) near the start codon can improve ribosome recognition and increase protein expression. In circRNA, the Kozak sequence is often positioned adjacent to an IRES to enable efficient and cap-independent translation.
[0065] In some embodiments, the circular RNA comprises a codon-optimized coding sequence (CDS) for a molecule of interest (e.g., CFTR). In some embodiments, the coding sequence is codon-optimized for expression in human cells. Codon optimization may improve translational efficiency and protein expression levels from the circular RNA.
[0066] In some embodiments, the circular RNA comprises at least one chemical modification or chemically modified base or nucleoside. The chemical modifications may comprise any modification which is not naturally present in the RNA or any naturally-occurring modification of adenosine (A), guanosine (G), uridine (U), or cytidine (C) ribonucleosides. In some embodiments, every particular base or nucleoside may be modified (e.g., every uridine is a modified uridine) In some embodiments, a particular modification is used for every particular type of nucleoside or base (e.g., every uridine is modified to a 1-methyl-pseudoundine). Exemplary RNA modifications can be found in the RNA modification database (mods.ma.albany.edu / home). Modified residues may be included in transcription reactions to generate modified RNA.
[0067] In some embodiments, the at least one chemical modification comprises a modified uridine residue. Exemplary nucleosides having a modified uracil include pseudouridine ( ), pyridin-4-one ribonucleoside, 5-aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine, 4-thio-uridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uridine, 5-aminoallyl-uridine, 5-halo-uridine (e.g., 5-iodo-uridine or 5 -bromo-uridine), 3-methyl-uridine, 5-methyl-undine, 5-methoxy-uridine, uridine 5-oxyacetic acid, uridine 5-oxyacetic acid methyl ester, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uridine, 5-carboxyhydroxymethyl-uridine methyl ester, 5-methoxycarbonylmethyl-uridine, 5-methoxycarbonylmethyl-2 -thio-uridine, 5-aminomethyl-2-thio-uridine, 5-methylaminomethyl-uridine, 5-methylaminomethyl-2-thio-uridine, 5-methylaminomethyl-2-seleno-uridine, 5-carbamoylmethyl-uridine, 5-carboxymethylaminomethyl-uridine, 5-carboxymethylaminomethyl-2-thio-uridine, 5-propynyl-uridine, 1 -propynyl-pseudouridine, 5-taurinomethyl-uridine, I-taurinomethyl-pseudouridine, 5-taurinomethy 1-2 -thio-uridine, l-taurinomethyl-4-thio-pseudouridine, 1-methylpseudouridine, 5-methyl-2-thio-uridine, l-methyl-4-thio-pseudouridine, 4-thio-l-Docket No. UM-44842.601methyl-pseudouridine, 3-methyl-pseudouridine, 2-thio-l-methyl-pseudouridine, 1-methyl-l-deaza-pseudouridine, 2-thio- 1 -methyl- 1 -deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, 1 -methylpseudouridine, 3-(3-amino-3-carboxypropyl)uridine, l-methyl-3-(3-amino-3-carboxypropyl)pseudouridine , 5- (isopentenylaminomethyl)uridine, 5-(isopentenylaminomethyl)-2-thio-uridine, a-thio-uridine, 2’-O-methyl-uridine, 5,2’ -O-dimethyl-uri dine, 2’-O-methyl-pseudouridine, 2-thio-2’-O-methyl-uridine, 5-methoxycarbonylmethyl-2’-O-methyl-uridine, 5-carbamoylmethyl-2’-O-methyl-uridine, 5-carboxymethylaminomethyl-2’-O-methyl-uridine, 3,2'-O-dimethyl-uridine, 5-(isopentenylaminomethyl)-2'-O-methyl-uridine, 1 -thio-uridine, deoxythymidine, 2’-F-ara-uridine, 2’-F-uridine, 2’-OH-ara-uridine, 5-(2-carbomethoxyvinyl) uridine, and 5-[3-(l-E-propenylamino)uridine. In some embodiments, the modified uridine residue is selected from the group consisting of: pseudouridine, 1 -methylpseudouridine, 1 -ethylpseudouridine, 2-thiouridine, 4'- thiouridine, 5-methyluridine, 2-thio-l -methyl- 1 -deaza-pseudouridine, 2- thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-l-methyl-pseudouridine, 4-thio-pseudouridine, 5 -aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2'-0-methyl uridine.
[0068] In some embodiments, the at least one chemical modification comprises a modified cytosine residue. Exemplary nucleosides having a modified cytosine include 5-aza-cytidine, 6-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetyl-cytidine. 5-formyl-cytidine, N4-methyl-cytidine, 5-methyl-cytidine, 5-halo-cytidine, 5-hydroxymethyl-cytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-l-methyl-pseudoisocytidine, 4-thio-l-methyl-I-deaza-pseudoisocytidine, 1-methyl-I-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2 -methoxy -5-methyl-cytidine, 4-methoxy -pseudoisocytidine, 4-methoxy-l-methyl-pseudoisocytidine. lysidine, a-thio-cytidine, 2’-O-methyl-cytidine. 5,2’ -O-dimethyl-cyti dine, N4-acetyl-2’-O-methyl-cytidine, N4,2’-O-dimethyl-cytidine, 5-formyl-2’-O-methyl -cytidine, N4,N4,2’-O-trimethyl-cytidine, 1 -thio-cytidine, 2’-F-aracytidine, 2’-F-cytidine, and 2’-OH-aracytidine. In some embodiments, the at least one chemical modification comprises 5-methylcytosine (base) or 5-methylcytidine (nucleoside). In some embodiments, the at least one chemical modification comprises 5 -methylcytosine.Docket No. UM-44842.601
[0069] In some embodiments, the at least one chemical modification comprises a modified adenine residue. Exemplary nucleosides having a modified adenine include 2-amino-purine, 2,6-diaminopurine, 2-amino-6-halo-purine, 6-halo-purine, 2-amino-6-methyl-purine, 8-azido-adenosine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-amino-purine, 7-deaza-8-aza-2-amino-purine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyl-adenosine, 2-methyl-adenine, N6-methyl-adenosine, 2-methylthio-N6-methyl-adenosine, N6-isopentenyl-adenosine, 2-methylthio-N6-isopentenyl-adenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, N6-glycinylcarbamoyl-adenosine, N6-threonylcarbamoyl-adenosine, N6-methyl-N6-threonylcarbamoyl-adenosine, 2-methylthio-N6-threonylcarbamoyl-adenosine, N6,N6-dimethyl-adenosine, N6-hydroxynoryalylcarbamoyl-adenosine, 2-methylthio-N6-hydroxynoryalylcarbamoyl-adenosine, N6-acetyl-adenosine. 7-methyl-adenine, 2-methylthio-adenine, 2-methoxy-adenine, a-thio-adenosine, 2’-O-methyl-adenosine, N6,2’-O-dimethyl-adenosine, N6,N6,2’-O-trimethyl-adenosine, l,2’-O-dimethyl-adenosine, 2’-O-ribosyladenosine (phosphate), 2-amino-N6-methyl-purine, 1 -thio-adenosine, 8-azido-adenosine, 2’-F-ara-adenosine, 2’-F-adenosine, 2’-OH-ara-adenosine, and N6-(19-amino-pentaoxanonadecyl)-adenosine.
[0070] In some embodiments, the at least one chemical modification comprises a modified guanine residue. Exemplary nucleosides having a modified guanine include inosine, 1 -methylinosine, wyosine, methylwyosine, 4-demethyl-wyosine. isowyosine, wybutosine, peroxywybutosine, hydroxywybutosine. undermodified hydroxy w butosine. 7-deaza-guanosine, queuosine, epoxy queuosine, galactosyl-queuosine, mannosyl-queuosine, 7-cyano-7-deaza-guanosine, 7-aminomethyl-7-deaza-guanosine, archaeosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine. 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methyl-inosine, 6-methoxy-guanosine, 1-methyl-guanosine, N2-methyl-guanosine, N2,N2-dimethyl-guanosine, N2,7-dimethyl-guanosine, N2,N2,7-dimethyl-guanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, N2.N2-dimethyl-6-thio-guanosine, a-thio-guanosine, 2’-O-methyl-guanosine, N2-methyl-2’-0-methyl-guanosine. N2,N2-dimethyl-2’-O-methyl-guanosine, l-methyl-2’-O-methyl-guanosine, N2,7-dimethyl-2’-O-methyl-guanosine, 2’-O-methyl-inosine, l,2’-O-dimethyl-inosine, and 2’-O-ribosylguanosine (phosphate).
[0071] In some embodiments, the composition of the present technology may be used for the treatment or prevention of a pulmonary disease. In some embodiments, the pulmonary diseaseDocket No. UM-44842.601is cystic fibrosis (CF). In some embodiments, the compositions of the present technology may be administered through a variety of routes to achieve the desired therapeutic effect. In some embodiments, the composition is administered intramuscularly, orally, intranasally, via pulmonary administration, or a combination thereof. In the present disclosure, the terms “intranasal delivery ” and “pulmonary' delivery” are used interchangeably to refer to delivery' of compositions to the respiratory’ tract of a subject.
[0072] In some embodiments, the intranasal route of administration may be employed, where the composition is formulated for intranasal delivery, such as in the form of sprays, drops, or aerosols. This method offers a non-invasive and potentially faster route to deliver the composition directly to the respiratory system, particularly for local effects or for targeting pulmonary diseases such as CF. The specific dosage and administration regimen will depend on factors such as the age, health, weight, and medical condition of the recipient, as well as the frequency of treatment and the desired therapeutic effect.
[0073] Similarly, pulmonary delivery’ may be utilized, where the composition is formulated for inhalation via devices such as nebulizers, dry powder inhalers, or metered-dose inhalers. Pulmonary delivery allows the composition to directly reach the lungs, which is beneficial for treating respiratory conditions such as asthma or cystic fibrosis. The exact dosage and administration schedule will be tailored based on the patient's needs, considering variables such as the patient’s lung function, disease severity, and concurrent treatments.
[0074] In some embodiments, the oral route of administration may be employed, where the composition is formulated for oral delivery, such as in the form of tablets, capsules, or liquid suspensions. This method provides a convenient and non-invasive administration option, particularly for patients who require chronic treatment. The specific dosage and administration regimen will depend on factors including the age, health, weight, and medical condition of the recipient, as well as the nature of any concurrent treatments, the frequency of treatment, and the desired therapeutic effect.
[0075] In some embodiments, the composition of the present technology' may be utilized for targeted delivery to the lungs or other affected organs, specifically for the treatment of pulmonary diseases such as CF. In some embodiments, the subject has or is at risk for a pulmonary disease. In some embodiments, the pulmonary disease is CF. The composition may be encapsulated in LNPs to protect the RNA from enzymatic degradation, improve cellular uptake, and facilitate effective passage through the mucus barrier characteristic of CF airways. These LNPs can be further engineered with surface modifications, such as PEGylation or pulmonary surfactant coatings, to enhance mucus penetration and promote retention in theDocket No. UM-44842.601airway epithelium. In some embodiments, the LNPs may include ligands that preferentially bind to receptors on specific pulmonary epithelial cell, such as ciliated cells or ionocytes, thereby improving targeted delivery of the RNA cargo and increasing therapeutic efficacy within diseased lung tissue.
[0076] Thus, the present compositions may be administered via a wide range of routes and dosing strategies, allowing for personalized treatment regimens that optimize therapeutic outcomes for the treatment of pulmonary disease such as CF. In some embodiments, the administering results in restoration of physiological function of CFTR to transport Cl- across cell membranes of bronchial epithelial cells.
[0077] In some embodiments, the composition is administered intranasally for the treatment of cystic fibrosis-associated rhinosinusitis (CFAR) or chronic rhinosinusitis (CRS). In some embodiments, intranasal administration comprises instilling about 10 micrograms to about 100 micrograms of RNA (e.g., about 30 micrograms) in about 0.1 mL to about 0.5 mL (e.g., about 0.3 mL) of a pharmaceutically acceptable carrier per nostril. In some embodiments, the composition is administered repeatedly over a treatment course. In some embodiments, the composition is administered once weekly. In some embodiments, the composition is administered once weekly for at least about 4 weeks. In some embodiments, the administering results in improvement of lung ventilation in the subject. In some embodiments, the improvement of lung ventilation comprises a reduction in ventilation defect percentage (VDP) and / or a reduction in ventilation heterogeneity (VH) (e.g., as measured by four-dimensional computed tomography (4D-CT) ventilation imaging). In some embodiments, the administering results in restoration of CFTR function for at least about 7 days following a single administration. In some embodiments, the restoration of CFTR function is measured by nasal potential difference (NPD) assay, Ussing chamber assay, automated conductance assay, or a combination thereof.
[0078] With respect to treatment of CF, the technology provided herein is agnostic to the mutation or mutations underlying the disease for any particular patient. As such, the technology finds use with CF patients having any one or more CF mutations. CFTR mutations are broadly categorized into six functional classes (Class I— VI) based on the specific defect they introduce into the CFTR protein biosynthesis or activity pathway. These classes include: Class I, characterized by defective protein synthesis, where premature stop codons or frameshift mutations prevent the production of any functional CFTR protein; Class II, involving protein processing defects, where misfolded CFTR protein is recognized and degraded by the cellular quality control machinery before reaching the cell surface; Class III, encompassing gatingDocket No. UM-44842.601defects, where the CFTR protein reaches the plasma membrane but fails to open correctly to allow chloride ion transport; Class IV, defined by conduction defects, in which the CFTR channel is present at the cell surface and may open normally but exhibits reduced ion flow due to altered channel pore properties; Class V, associated with reduced protein synthesis, often due to splicing or promoter mutations that result in decreased quantities of functional CFTR at the membrane; and Class VI, involving protein instability, where the CFTR protein is produced and delivered to the cell surface but is rapidly degraded due to impaired membrane retention. In some embodiments, a single mutation may exhibit features of more than one class. Table 4 shows a list of exemplary class I-VI mutations.Docket No. UM-44842.601Table 4: Classification of CFTR mutationsClassification MutationsClass I 1078delT, I 154insTC, 1525-2A > G, 1717-1G > A, 1898+1G > A,2184delA, 2184msA, 3007delG, 312O+1G> A, 3659delC, 3876delA, 3905msT, 394delTT, 4010del4, 4016msT, 4326delTC, 4374+1G > T, 441delA, 556delA, 621+1O T, 621-1G > T. 711+1G>T, 875+lG > C, E1104X, E585X, E60X, E822X, G542X, Q493X. Q552X, Q814X, R1066C, R1162X, R553X, V520F, W1282X, Y1092X, 2183AA>G, R1158X, K710XClass II A559T. D979A, AF508 (F5O8del). AI507 (L5O7del), G480C, G85E.N1303K, S549I. S549N, S549R, L206WClass III G1244E, G1349D, G551D, G551S, G85E, H199R, I1072T, 148T, L1077P, R560T, S1255P, S549(R75Q), S549N, S549R Class IV A800G, DI 152H, DI 154G. D614G, delMl 140. E822K, G3I4E. G576A,G622D. G85E, H620Q, I1139V, I1234V, L1335P, Ml 137V, P67L, R117C, R117P, R117H, R334W, R347H, R347P, R347P / R347H, R792G, SI 25 IN, V232DClass V 3849+lOkbOT, 2789+5G>A, 3272-26A+G, 3846G>A Class VI 2789+5G > A. 3120G > A, 3272-26A > G, 3849+lOkbC > T, 5T variant,621+3 A > G, 711+3A > G, A445E, A455E, IVS8 poly T, P574H,4326delTC, 4279insA. R1070Q[0079J In some embodiments, the patient may have a CFTR class I mutation. In some embodiments, the patient may have a CFTR class II mutation. In some embodiments, the patient may have a CFTR class 111 mutation. In some embodiments, the patient may have a CFTR class IV mutation. In some embodiments, the patient may have a CFTR class V mutation. In some embodiments, the patient may have a CFTR class VI mutation. In some embodiments, a patient may cany one or more mutations in the CFTR gene associated with cystic fibrosis. These mutations may occur on one or both alleles and may differ in type and clinical significance. In some embodiments, the patient may be a homozygote, carrying two identical mutations, which may belong to the same functional classes. In other embodiments, the patient may be a compound heterozygote, carry ing two different CFTR mutations, which may belong to the same or different functional classes.Docket No. UM-44842.601
[0080] In some embodiments, prior to treatment, a patient is tested to identify CF. In some embodiments, the testing comprises genetic testing methodologies, including but not limited to, next-generation sequencing, allele-specific PCR, multiplex PCR, microarray -based assays, or full CFTR gene sequencing. Genetic material for such analyses may be obtained from a variety of biological samples, including but not limited to, blood, saliva, and / or other bodily fluids. In certain embodiments, CFTR mutation testing may be conducted as part of newborn screening programs, where a sample is analyzed to detect potential indicators of cystic fibrosis. In some embodiments, diagnostic testing is performed in individuals with clinical features suggestive of cystic fibrosis, to confirm a diagnosis and characterize the specific CFTR genotype. In other embodiments, carrier screening may be used to determine whether an asymptomatic individual carries a CFTR mutation. In further embodiments, expanded CFTR mutation panels may be employed, including a broader array of known mutations beyond the standard panels. In some embodiments, full CFTR gene sequencing may be utilized to detect both common and rare mutations, including novel variants not detected by targeted panels. In some embodiments, the identification of the mutation class may further be used to monitor disease progression, predict clinical outcomes, or guide ongoing therapeutic adjustments.
[0081] In some embodiments, the patient has a CFTR null mutation (e.g., a Class I mutation such as G542X). Patients wi th null mutations do not produce full-length CFTR protein and are ineligible for current CFTR modulator therapy (e.g., elexacaftor-tezacaftor-ivacaftor (ETI)). In some embodiments, the compositions and methods provided herein restore CFTR expression and function in cells carrying a null mutation. In some embodiments, the patient has a CFTR gating mutation (e.g., a Class III mutation such as G551D).
[0082] In some embodiments, the compositions and methods find use in the treatment or prevention of diseases or conditions that are the result of complications of CF. For example, in some embodiments, is the compositions and methods find use in the treatment or prevention of cystic fibrosis-associated rhinosinusitis (CFAR). CFAR is associated with the accumulation of viscous mucus in various organs, including the airways and nasal sinuses. This mucus buildup can obstruct sinus drainage and contribute to chronic inflammation. Symptoms of CFAR present with characteristic clinical features, which may include, but are not limited to, chronic nasal congestion, postnasal drip, mucopurulent nasal discharge, facial pain or pressure, headaches, hyposmia or anosmia (partial or complete loss of smell), and the presence of nasal polyps.
[0083] In some embodiments, abnormal mucus production in the nasal cavity leads to impaired mucociliary clearance, fostering an environment conducive to chronic sinus infections.Docket No. UM-44842.601inflammation, and obstruction. Consequently, patients with cystic fibrosis frequently experience persistent nasal congestion, rhinitis, and facial pain, which can significantly impact quality of life.
[0084] In some embodiments, management of CFAR involves a multimodal approach, including but not limited to, combination treatments including nasal saline irrigation, topical corticosteroids, antibiotic therapy (topical or systemic), and CFTR modulator treatments where applicable. In some embodiments, functional endoscopic sinus surgery (FESS) may be employed to restore sinus drainage and reduce disease burden.
[0085] Embodiments of the disclosure provide kits and devices for utilizing the compositions described herein. Devices may be provided pre-loaded with one or more doses of a composition of the present disclosure. Alternately, devices may be provided separately from the composition (e.g., as a component of a kit for treatment of a subject).
[0086] Examples of deliver}' devices for pulmonary (e.g., intranasal or directly to the lung) delivery' include but are not limited to, a metered dose inhaler, a dry powder inhaler, a metered dose spray pump, a soft mist inhaler, or a nebulizer.
[0087] Metered-dose spray pumps and nebulizers are the most frequently used devices for nasal delivery. Metered-dose spray pumps can deliver a precise and constant volume of drug solution or suspension with adjustable particle sizes and geometries (Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res 2013;3:42e62) and provide the advantages of low manufacturing costs, portability, simplicity in applications, and safety. Single-dose metered-dose spray pumps are available, for example, from BD (Accuspray™ device).
[0088] Medical nebulizers like vibrating mesh, air-jet, and ultrasonic nebulizers can also be utilized for intranasal administration. OptiNose is a bi-directional nasal nebulizer that includes a flexible mouthpiece and a sealing nosepiece (Djupesland PG, Skretting A, Winderen M, Holand T. Breath actuated device improves deliver}' to target sites beyond the nasal valve. Laryngoscope 2006;116:466e72). The device isolates the nose from the mouth and lungs through automatic closure of the soft palate during oral exhalation and helps the composition to deposit in high / deep sites in the nasal passages.
[0089] For pulmonary delivery directly to the lung, exemplary devices include pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), and nebulizers (Rau JL. Design principles of liquid nebulization devices currently in use. Respir Care 2002;47:1257e78).
[0090] Pressurized metered dose inhalers (pMDIs) use pressurized propellant to deliver a fixed dose of aerosol through a nebulizer nozzle. The canister, metering valve, actuator, and doseDocket No. UM-44842.601counter are the major components of pMDIs. The canister contains a mixture of propellant, drugs, and excipients.
[0091] Soft mist inhalers (SMIs) are propellent-free metered-dose inhalers activated by breathing (Tamura G. Comparison of the aerosol velocity of Respimat soft mist inhaler and seven pressurized metered dose inhalers. Allergol Int 2015;64:390e2; Brand P, Hederer B, Austen G, Dewberry H, Meyer T. Higher lung deposition with Respimat Soft MistTM Inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis 2008;3:763e70). These deliver aqueous formulations through micro holes, forming soft fog for deep lung deposition. The aerosol generated with SMIs generally has a high fine particle fraction (65%e80%), a low velocity, and a more sustained duration than that of pMDIs (Dalby R, Spallek M, Voshaar T. A review of the development of Respimat soft MistTM inhaler. Int J Pharm 2004;283: le9. 277. Hochrainer D, Ho "lz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft MistTM Inhaler and pressurized metered dose inhalers. J Aerosol Med 2005;18:273e82).
[0092] Unlike pMDIs, DPIs are breath-actuated devices, that can be used for the respiratory administration of either single or multidose dry powders. Examples include, for example, BD Solovent, Aktiv-Dry, Aerolizer, Diskus, Flexhaler, Handihaler, Neohaler, Pressair, Rotahaler, Turbohaler, and Twisthaler. Other dry powder inhalers which can be used are described in US patent 6,766,799, US pa-tent 7,278,425 and US patent 8,496,002, each of which are hereby incorporated by reference in their entireties.
[0093] Nebulizers like vibrating mesh, surface acoustic wave (SAW), air-jet, and ultrasonic nebulizers generate large volumes of inhalable aerosols, where the loaded formulations do not require propellant as in pMDIs or drying processes as in DPIs. Air-jet nebulizers employ high-velocity gas to pass through a venturi nozzle and convert liquids into a mist. The liquid is drawn from the nebulizer reservoir up to a feed tube and emerges as fine filaments that collapse into aerosol droplets. Unlike jet nebulizers, ultrasonic nebulizers exploit a piezoelectric cry stal vibrating at high frequency7to produce a fountain at the liquid-air interface, which forms droplets that can be aerosolized and exit the nebulizer through ventilation (Flament MP, Leterme P. Gayot A. Study of the technological parameters of ultrasonic nebulization. Drug Dev Ind Pharm 2001;27:643e9).
[0094] Similar to ultrasonic nebulizers, mesh nebulizers are more portable and efficient than jet nebulizers, but they are less effective with viscous solutions and suspensions due to their ability to clog the pores. Vibrating mesh nebulizers are commonly used to deliver respiratory-delivered compositions.Docket No. UM-44842.601
[0095] Any of the compositions described herein may be included in a kit. For example, compositions, delivery devices, delivery devices loaded with compositions, and the like.
[0096] Such kits generally will comprise, in suitable means, distinct containers for each individual reagent or solution. The kit may comprise one or more containers holding the compositions, and other agents. Suitable containers for the compositions include, for example, bottles, vials, syringes, and test tubes. Containers can be formed from a variety of materials, including glass or plastic. A container may have a sterile access port (for example, the container may be a vial having a stopper pierceable by a hypodermic injection needle).
[0097] The kit can further comprise a container comprising a pharmaceutically acceptable buffer, such as phosphate-buffered saline, Ringer's solution, or dextrose solution. It can also contain other materials useful to the end-user, including other pharmaceutically acceptable formulating solutions such as buffers, diluents, filters, needles, and syringes or the pulmonary delivery devices described herein. The deliver}' device may be pre-filled with the compositions.
[0098] It will be readily apparent to those skilled in the art that other suitable modifications and adaptations of the methods of the present disclosure described herein are readily applicable and appreciable and may be made using suitable equivalents without departing from the scope of the present disclosure or the aspects and embodiments disclosed herein. Having now described the present disclosure in detail, the same will be more clearly understood by reference to the following examples, which are merely intended only to illustrate some aspects and embodiments of the present disclosure and should not be viewed as limiting to the scope of the disclosure. The disclosures of all journal references, U.S. patents, and publications referred to herein are hereby incorporated by reference in their entireties.EXAMPLES
[0099] The present disclosure has multiple aspects, illustrated by the non-limiting examples as described herein.
[0100] It is understood that the foregoing detailed description and accompany ing examples are merely illustrative and are not to be taken as limitations upon the scope of the disclosure, which is defined solely by the appended claims and their equivalents.Example 1:Materials and Methods
[0101] circRNA synthesis. Circular RNA (circRNA) encoding wildtype functional cystic fibrosis transmembrane conductance regulator (CFTR) protein (circRNA-CFTR) (NCBI:Docket No. UM-44842.601NM_000492.3) and circRNA encoding firefly luciferase (circRNA-fLuc) were synthesized in two steps
[0051] : (1) IVT using AmpliScribe T7 High Yield Transcription Kit (Biosearch Technologies, AS3107), and (2) group I intron-mediated autocatalytic circularization. Briefly, 1 pg DNA template was used per 20 pL IVT reaction (37 °C, 2 hours). Then, DNA templates were degraded with DNase I (37 °C, 15 minutes). The remaining RNA was column purified. Next. GTP (2 mM) was added to the resulting RNA to allow autocatalytic RNA cyclization (55 °C, 15 minutes). circRNA was column purified using an RNA Clean & Concentrator kit (Zymo Research) or HPLC to remove DNA or RNA fragments, nucleotides, and enzymes. circRNA products were verified using gel electrophoresis.
[0102] In vitro circRNA stability. To study thermostability, circRNA and modified mRNA were stored in PBS at 4 °C, 25 °C. and -20 °C for a series of time. The remaining RNAs were resolved by agarose gel electrophoresis and imaged using a ChemiDoc Imaging System (BioRad Laboratories). Intact RNA was quantified using ImageJ software (NIH, Bethesda, MD). To study the in vitro biostability7of circRNA and modified mRNA, RNA was incubated in freshly prepared diluted fetal bovine serum (FBS) (37°C, 30 minutes), and was then briefly denatured in RNA loading buffer before gel electrophoresis. Intact RNA was quantified.
[0103] Formulation. An ethanol phase containing all lipids, and an aqueous phase of RNA were mixed to synthesize LNPs. The ethanol phase contained ionizable lipids, DSPC, DMG-PEG2000, and cholesterol at a molar ratio of 50: 10: 1.5: 38.5. The aqueous phase contained circRNA or mRNA in 10 mM citrate buffer. The two phases were mixed at a flow rate of 1.8 and 0.6 mL / min (3:1), respectively, using Pump33DS syringe pumps. LNPs were dialyzed in lx PBS in a microdialysis cassette (20,000 MWCO, Thermo Fisher Scientific, Waltham, MA) at 4 °C for 12 hours. LNP diameters and poly dispersity index (PDI) were measured on Zetasizer Nano (Malvern Instruments, Malvern, U.K.). RNA concentration and encapsulation efficiency in LNPs were measured using a modified Quant-iT RiboGreen (ThermoFisher) assay, and the circRNA copy numbers per LNP were estimated
[0052] , For cryo-EM, LNPs were concentrated after dialysis to ~90 mg / mL of lipid using Amicon ultracentrifugation filters before cryo-EM observation at the Molecular Electron Microscopy Core of University of Michigan.
[0104] Cell Culture. Cystic Fibrosis (CF) cells (RRID: CVCL HL93), which are derived from a patient homozygous for the F508del mutation, were used as an in vitro model system for cystic fibrosis. To study normal CFTR behavior, CF cells were used and stably transfected with an Epstein-Barr virus (EBV)-based episomal expression vector, pCEP4b (CF-WT)
[0053] , All cell lines were purchased from Sigma. Cells were grown in minimal essential medium supplemented with 10% regular fetal bovine serum (Coming) and 5%Docket No. UM-44842.601penicillin / streptomycin / glutamate (Coming) at 37 °C, supplemented with 5% CO2, and cultured between 20%-80% confluency on 10-cm culture dishes (Coming).
[0105] Animals. All animal work was conducted in compliance with the University of Michigan Guide for the Care and Use of Animals under protocols approved by the University of Michigan Animal Care and Use Committee. Female BALB / c mice (Charles River Laboratories) were sedated using isoflurane (2%), and LNP-circRNA-Fluc / mRNA-Fluc were intratracheally administered into the lungs (0.6 mg / kg). Bioluminescent imaging was performed using the IVIS Lumina XRMS imaging system (PerkinElmer) following an intraperitoneal injection of 200 rnL of D-luciferin substrate (PerkinElmer, 150 mg / kg body weight). Image acquisition and analysis were conducted using IVIS Living Image software (PerkinElmer).
[0106] Cftr / tmlUnc Tg(FABPCFTR)! Jaw / J double-transgenic CFKO mice were obtained from The Jackson Laboratory (JAX 002364). Mice were produced with full knockout of the endogenous mouse gene Cftr. To avoid complications in the intestines associated with Cftr knockout, the human CFTR (hCFTR) transgene was complimented back using fatty acid binding protein 2 (FABP2) as a promoter, resulting in localized hCFTR expression in the gastrointestinal tract
[0054] .
[0107] Lucifei ’ase Assay. Cells were plated 24 hours prior to transfection. LNP-circRNA-FLuc / mRNA-FLuc was exposed to cells, and after 24 hours, luciferase expression (One-Gio Luciferase Assay, Promega) was measured
[0055] ,
[0108] Western Blot. Sodium dodecyl sulfate-polyacrylamide gel (Thermofisher) electrophoresis was used to separate proteins, which were then transferred to PVDF membranes(Bio-Rad). The primary antibodies listed in Table 1 and the appropriate HRP -linked anti-rabbi t / anti-mice IgG secondary antibodies (CST) were incubated with the membranes. An enhanced chemiluminescent substrate kit (Thermofisher) was used to detect the blots with Image LabTM software (Bio-Rad).
[0109] Flow Cytometry7. Flow7cytometry7w as used to analyze cells and tracheal and lung tissue homogenate single cells. The antibodies used for immunostaining are listed in Table 1. Cultured cells and tissue single cells were analyzed on LSRFortessa X-50 (BD Biosciences). Flow cytometry results were analyzed using FlowJo V10 software.
[0110] Immunofluorescence staining. Formalin -fixed, paraffin Section (4 pm) of pulmonary tissues fixed with 4% PFA and permeabilized with 0.25% Triton X100 were stained with primary7antibodies (details in Table 1). Alexa Fluor 488-conjugated anti-rabbit IgG (Invitrogen) and Alexa Fluor 594-conjugated anti-rabbit IgG (Invitrogen,) were used asDocket No. UM-44842.601secondary antibodies. DAPI (Santa Cruz Biotechnology) was used to detect nuclei. A Leica TCS SP2 confocal laser scanning microscope was used to capture images.Docket No. UM-44842.601
[0112] Table 1 Primary AntibodiesAntigens Manufacturer Catalog Number Application CFTR CELL SIGNALING TECHNOLOGY 78335 S 1:1000 FOR WB CFTR Novus BIOLOGICALS NBP2-54504PE 1:100 FOR FLOW CFTR ABCAM AB131553 1:500 FOR IF HOP SANTACRUZ SC-398703 1:100 FOR IF MUCIN ABCAM AB3649 1:100 FOR IF TUBULIN MILLIPORE SIGMA T6793 1:100 FOR IF SCGB1A1 ABCAM AB40873 1:100 FOR IF ACTIN CELL SIGNALING TECHNOLOGY #4979S 1:1000 FOR WB
[0113] Measurements of short-circuit current (Isc) by Ussing chamber. Iscrecordings in Ussing chambers were conducted on ex vivo intestinal and tracheal preparations, as well as in vitro airway epithelial cell cultures [56-59], After equilibration, Fsk (1 x 10-5 M, bilateral), bumetanide (1 x 10-4 M, basolateral), glucose (5 mM, apical), and phloridzin (1 x 10-4 M, apical; MilliporeSigma) were sequentially added and changes in Iscmeasured. Tracheal preparations were prepared as 4 cm-long sections excised and immediately placed into Ringer’s buffer (120 mM NaCl, 25 mMNaHCCh, 3.3 mM KH2PO4. 0.8 mM KH2PO4, 1.2 mM MgCl2, 1.2 mM CaCl2, and 10 mM glucose) with 10 pM indomethacin (MilliporeSigma), that was continuously gassed with 95% O2and 5% CO2for 10 minutes. After incubation, connective tissues were removed from the trachea under a dissection microscope. A longitudinal cut was made along the trachea, exposing the mucosal side. The tracheal epithelium was carefully placed on a slider with an exposed surface area of 0.20 cm2. Both sides of the epithelium were perfused with equal amounts of Ringer’s buffer at 37°C and gassed with 95% O2and 5% CO2, providing gas lift circulation. Each sample was equilibrated under voltage clamp (Isc) conditions for 20 minutes. Once a baseline Iscwas achieved, drugs were added as follows: amiloride (apical, 1 x 10—5 M), Fsk (basolateral. 1 x 10-5 M), GlyHlOl (apical, 1 x 10-3 M, provided by R.Bridges, Chicago Medical School, North Chicago, Illinois, USA), and bumetanide (basolateral, 1 x 10-3 M). Isolation of airway epithelial cells from rabbit trachea to generate primary' cultures was performed
[0058] , with the following modifications: the connective tissue surrounding freshly excised tracheas was removed by fine dissection, and the trachea was cut in short segments and opened longitudinally to expose the airway epithelium.Docket No. UM-44842.601Tracheal segments were placed in digestion solution (1% Protease XIV with DNase; amphotericin [MilliporeSigma], 1:200; gentamicin [MilliporeSigma], 1:1000; in F12 medium [Thermo Fisher Scientific]) on a rocker in cold room overnight (4°C). Declumping was performed for 15 minutes using 1-3 mL of Accutase Cell Detachment Solution (Innovative Cell Technologies) at 37°C, and cells were seeded on 12 mm Millicell Cell Culture Inserts (MilliporeSigma) and grown for about 21 days until air-liquid interface was established. Ussing chamber electrophysiology was performed on these cultures [60, 61],
[0114] Statistical analysis. Data are presented as mean ± S.E.M., unless noted otherwise. Statistical analysis was conducted using GraphPad Prism Software version 5.0. P-values were calculated using one-way ANOVA with Bonferroni post-test unless noted otherwise.
[0115] QCM-D measurements. QCM-D measurements were performed using a QSense Analyzer instrument equipped with standard modules (Biolin Scientific). Supported PS single layer was prepared by deposition of Curosurf on a SiC>2 surface. SiC surfaces were treated with divalent calcium cations (CaCh) at a concentration of 2 rnM for 5 minutes before forming the PS layer. Supported PS layer was formed by deposition and fusion of Curosurf SUVs (z-average of approximately 64.0 nm) in MQ (0.1 mg / mL in MQ) at a flow rate of 100 microliters / min at 50.0 degrees C using an external peristaltic pump in the presence of 2 mM Ca2+. When stable readings from the instrument were observed. CF-mimicking buffer (10 mM acetate buffer at pH 5.6 supplemented with 150 mM NaCl) was injected. The PS layer was then exposed to 0.1 mg / mL LNPs for 20 minutes, followed by incubating the LNPs with PS for an additional 60 minutes, and rinsing with the corresponding buffer for 20 minutes.
[0116] Proteomic analysis of nanoparticle protein corona by LC-MS / MS. For proteomic analysis, LNPs and BALF were incubated at 37 degrees C for 10 minutes to allow equilibration, followed by an additional 30 minutes incubation at room temperature prior to separation. BALF was pre-purified to remove cells and cellular vesicles. Free proteins present in LNP / BALF were removed using an extracellular vesicle separation column (STEMCELL Technologies), enabling enrichment of nanoparticle-associated protein components. For in-solution digestion, samples were reduced with dithiothreitol (DTT), alkylated with 2-chloroacetamide, and digested overnight with trypsin / LysC. Peptides were desalted using Sep-Pak Cl 8 cartridges, dried, and reconstituted in 0.1% formic acid / 2% acetonitrile. Peptide samples were loaded onto a nano-capillary reverse-phase column (Acclaim PepMap Cl 8, 2 micrometer particle size, 50 cm length; Thermo Fisher) and separated using a linear gradient at a flow- rate of 300 nL / min. Eluted peptides were introduced into an Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher) via an EasySpray ion source. Proteins were identified by searching the MS / MS dataDocket No. UM-44842.601against a Mus musculus database using Proteome Discoverer (v3.0, Thermo Fisher). False discovery’ rate was determined using Percolator and proteins / peptides with an FDR of 1% or less were retained for further analysis.
[0117] Mucus transport study. To study' mucus transport for RNA-loaded LNPs and psLNPs, 1 microgram Cy5-labeled circRNA-CFTR loaded in psLNPs and LNPs, respectively, were gently applied to the apical surface of each Transwell insert without disturbing the mucus layer. Prior to confocal microscopy, cells were stained from the basolateral side with Hoechst 33342 (1 microgram / mL in basolateral medium, 10-15 minutes at 37 degrees C). At 0.5, 1, and 2 hours after apical RNA application, Z-stack images (50 micrometer step size, spanning approximately 300 micrometers above the cell layer) were acquired using a confocal microscope. Z-stack image integrated intensity was quantified in ImageJ / Fiji using 3D objects count and 3D Manager.
[0118] Oxidative stress assay. For in vitro oxidative stress evaluation, LNPs were incubated with BALF to allow protein corona formation, followed by SEC purification and treatment of MH-S alveolar macrophage cells. Tert-butyl hydroperoxide (tBHP) served as a positive control for oxidative stress induction, and N-acetylcysteine (NAC) served as an antioxidant control. Oxidative stress was quantified by the percentage of oxidative stress-positive cells. For in vivo oxidative stress analysis, C57BL / 6 mice were administered LNP circRNA-CFTR or psLNP circRNA-CFTR intratracheally, followed by isolation of single lung cells for oxidative stress analysis by flow cytometry’.Example 2:circRNA design, synthesis, and characterization
[0119] The sequence utilized in the presently disclosed subject matter corresponds to the coding region (CDS) and represents a novel approach. The present invention focuses on the CDS. which is 1704 bp shorter than the full-length sequence (4443 bp compared to 6147 bp) (Fig. 2A). The pUC57 plasmid used for circRNA-CFTR synthesis comprised coding RNA for human CFTR that functions normally in mice, Permuted Intron-Exon I (PIE-I) self-splicing intron for RNA circularization, IRES which initiates CFTR translation, and spacer and homology arms that promote RNA circularization. circRNA was synthesized as follows: (1) linearized plasmid using restriction enzymes (Fig. 2B), (2) synthesized RNA precursor using linearized plasmid (1 pg) via IVT (20 pL) and AmpliScribe T7 High Yield Transcription Kit, prior to treatment with DNase I to remove plasmids and column-purification, (3) ~50 pg RNADocket No. UM-44842.601precursors were heat denatured, then GTP and T4 RNA ligase buffer was added for RNA circularization by self-ligating ribozyme in PIE-1,1,2 and (4) RNase R treatment for linear / lariat RNA removal before column purification (Fig. 2C).
[0120] In some embodiments, circRNA-CFTR comprises a codon-optimized coding sequence (CDS) for full-length human CFTR (4,443 nucleotides), a CVB3 IRES driving efficient protein translation, and a non-functional RNA residual sequence resulting from RNA circularization. circRNA was verified by gel electrophoresis and Sanger sequencing of the reverse-transcribed complementary DNA (cDNA) at the splice junction site, confirming precise splicing-mediated RNA circularization. Additionally, N1 -methylpseudouridine (mlpsi)-modified mRNA-CFTR (mlpsi-mRNA-CFTR) was synthesized as a benchmark of nucleotide-modified mRNA for comparison.Example 3:DOE study for the optimization of LNP for pulmonary delivery of circRNA.
[0121] LNPs were formulated using microfluidic mixing, allowing the lipids and RNA to spontaneously self-assemble into small, uniform nanostructures optimized for delivery. Given that different formulations exhibit varying levels of efficacy, a Design of Experiment (DOE) approach was utilized to systematically identify the most effective formulation (Table 2).
[0122] Table 2. Variables that are studied in DOE optimization of LNP formulations for circRNA fLuc delivery in vitro and in vivo.Factors RangeIonizable Lipid SM102, RCB4-8Surfactant (-), PS mixed. PS coated, Chitosin(mixed), Oligo-G( coated) Cargo circRNA-fLucTime point 12h,24h,48h,72h,96h
[0123] Next, the circRNA encapsulation efficiency, size, and zeta of LNPs using the RiboGreen Assay and Dynamic Light Scattering were evaluated, respectively. Dynamic light scattering (DLS) showed that LNPs had an average hydrodynamic size of 104.2 ± 30.5 nm and were uniform, with a polydispersify index (PDI) of 0.08 and high encapsulation efficiency (>95%) (Table 3). These characterizations indicated that LNPs can encapsulate large circRNA-CFTR molecules into nanoscale packages used for intracellular delivery'.Docket No. UM-44842.601
[0124] Table 3. Characterization of surfactant-coated or surfactant-mixed LNPs loaded with circRNA-fLuc.Ionizable Surfactant Size PDI Zeta Lipid potential 1 SM102 - - 118.8 0.1054 -1.434 2 SM102 PS 20% Coated 132.9 0.2029 -2 3 SM102 Oligo-G 10% Coated 110.2 0.1518 -6.703 4 SM102 Oligo-G 30% Coated 118.4 0.1841 -7.702 5 SM102 PS Mixed 107.5 0.1654 4.191 6 SM102 Chitosan 10:1 Mixed 106.7 0.2302 -0.1636 7 SM102 Chitosan 5: 1 Mixed 97.82 0.2 5.849 8 RCB-4-8 - - 100.4 0.0823 -5.683 9 RCB-4-8 PS Coated 120.9 0.1422 -3.712 10 RCB-4-8 Oligo-G 10% Coated 119.2 0.1565 -4.654 11 RCB-4-8 Oligo-G 30% Coated 123.5 0.1612 -5.395 12 RCB-4-8 PS Mixed 100.3 0.1475 1.048 13 RCB-4-8 Chitosan 10:1 Mixed 120.3 0.2027 -1.259 14 RCB-4-8 Chitosan 5: 1 Mixed 119.9 0.2441 -6.163
[0139] To study the in vitro uptake and efficacy of these LNPs, CF cells were employed, which were derived from a patient homozygous for the F508del mutation. As a positive control, CF cells were used and stably transfected with an Epstein-Barr virus (EBV)-based episomal expression vector (CF-WT cells). Particle efficacy in CF cells were evaluated using a bioluminescent reporter RNA encoding firefly luciferase (LNP-circRNA-fLuc) (Fig. 3A). The results demonstrated that the circRNA-fLuc exhibited both higher expression levels and longer-lasting activity, with formulations 1 (SM102), 2 (SM102 / 20% PS-coated) and 4 (SM102 / 30% Oligo-G-coated) showing the best performance among the tested formulations.
[0125] To further refine the formulation composition, a second DOE study was conducted to examine the impact of varying surfactant percentages (Table 4). The results indicated that formulation 1 (SMI 02) and formulation 3 (SMI 02 / 20% PS-coated) demonstrated the highest efficacy (Fig. 3B).Docket No. UM-44842.601
[0126] Table 4. Characterization of surfactant-coated SM-102 LNPs loaded with circRNA-fLuc.Surfactant Surfactant fraction Size PDI Zeta potential (w / w)1 - - 102.4 0.128 -1.923 2 PS 10% 139.5 0.1753 1.373 3 PS 20% 126.8 0.1715 0.5526 4 PS 30% 142.2 0.1892 0.8128 5 Oligo-G 10% 104.6 0.1148 -7.695 6 Oligo-G 20% 109.7 0.2212 -9.57 7 Oligo-G 30% 127.9 0.1892 -10.64
[0127] Different LNP-circRNA-FLuc formulations (0.6 mg / kg) were intratracheally administered to healthy BALB / c mice. Luciferase expression was detected in the trachea and lungs as early as 6 hours post-injection and peaked at 24 hours (Fig. 3C). Compared to formulation 1 (SM-102), formulation 3 (20% SMI 02 / 20% PS-coated) exhibited significantly higher luciferase expression at 6 hours and demonstrated greater in vivo durability at later time points. Based on these findings, formulation SMI 02 / 20% PS-coated was selected for subsequent experiments.
[0128] Different LNP-circRNA-fLuc formulations (10 micrograms RNA) were also intratracheally instilled into FVB mice. Luciferase expression was detected in the trachea and lungs as early as 6 hours post-instillation. Compared to formulation 1 (SM-102 alone), formulation 3 (SM102 / 20% PS-coated, also referred to herein as psLNPs (pul mon ar -surfactant-coated LNPs)) exhibited significantly higher luciferase expression at 6 hours and demonstrated greater in vivo durability at later time points, with reduced systemic dissemination relative to uncoated LNPs. Cryogenic electron microscopy (cryo-EM) imaging of circRNA-CFTR-loaded psLNPs revealed unique multilamellar shell structures surrounding the LNP core, distinct from the bleb-like structures observed in uncoated LNPs. indicating successful PS coating. Dynamic light scattering (DLS) confirmed a slight size increase of psLNPs relative to uncoated LNPs. Both LNPs and psLNPs tolerated six freeze-thaw cycles (between -80 degrees C and room temperature, 24 hours per cycle) in PBS supplemented with 10% sucrose cryoprotectant, with minimal changes in nanoparticle size, PDI. RNA encapsulation efficiency, or RNA expression efficiency.Docket No. UM-44842.601Example 4:CFTR expression kinetics and cellular physiology in CF cells.
[0129] To further validate these findings, cell-based experiments were conducted to examine CFTR expression and functionality in CFTR wildtype (WT) or CFTR-F508del human bronchial epithelial cells, referred to as CF-WT and CF cells, respectively. To evaluate CFTR expression over time under different treatments, flow cytometry analysis was conducted on days 1 through 14. The results demonstrated that LNP-circRNA-CFTR exhibited significantly more sustained and robust CFTR expression compared to LNP-mRNA-CFTR. Notably, by day 3, CFTR expression levels in the LNP-circRNA-treated group matched those of CF-WT cells and remained comparable until day 10 (Fig. 4A). Western blot analysis confirmed CFTR protein expression following LNP-circRNA / mRNA-CFTR treatment on day 3. The analysis revealed increased CFTR expression in cells treated with both LNP-circRNA-CFTR and LNP-mRNA-CFTR. However, CF cells treated with LNP-circRNA-CFTR showed markedly higher protein levels compared to those receiving LNP-mRNA-CFTR (Fig. 4B). Confocal microscopy was used to investigate the subcellular localization of CFTR. In CF-WT cells, CFTR demonstrated proper localization at the plasma membrane (Fig. 4C). In contrast, untreated CF cells showed premature processing arrest of CFTR within the endoplasmic reticulum, characterized by perinuclear accumulation. Treatment with LNP-circRNA-CFTR effectively restored CFTR localization to the plasma membrane in CF cells (Fig. 4C). To evaluate the functional restoration of CFTR, Ussing chamber experiments were conducted to measure chloride efflux on day 3 (Fig. 4D). Treatment with LNP-circRNA-CFTR resulted in a statistically significant increase in chloride efflux compared to untreated controls. Notably, the chloride channel responsiveness in the circRNA-treated group exceeded half the sensitivity observed in CF-WT cells and demonstrated superior effectiveness compared to the LNP-mRNA-CFTR-treated group (Fig. 4D). Together, these findings demonstrated that LNP-circRNA-CFTR undergoes efficient cellular processing, producing functional CFTR protein that closely replicates the localization and activity7of endogenous WT CFTR at the plasma membrane. This underscores the therapeutic utility of LNP-circRNA-CFTR for restoring CFTR functionality and addressing the underlying cause of CF.
[0130] To further evaluate the therapeutic breadth of LNP-circRNA-CFTR, experiments ere conducted in additional CF cell lines carry ing different CFTR mutations. In 16HBEge CFTR-G542X cells, which carry the most prevalent null mutation in CF patients, treatment with circRNA-CFTR-psLNPs recovered CFTR expression levels as shown by Western blot and immunofluorescence, outperforming mlpsi-mRNA-CFTR-LNPs as early as 3 days postDocket No. UM-44842.601treatment, and eventually outperforming circRNA-CFTR-LNPs by 7 days post-treatment. In 16HBE-F508del cells, an automated conductance (Gt) assay using a transepithelial cunent clamp (TECC) robotic system was used to evaluate CFTR electrophysiological function. circRNA-CFTR-LNPs facilitated dose-dependent CFTR activation, outperforming mlpsi-mRNA-CFTR-LNPs. Notably, circRNA-CFTR-LNPs comparably restored CFTR function relative to the clinical benchmark of VX-445 (elexacaftor) + VX-661 (tezacaftor). Additionally, at high RNA concentrations (e.g., about 4 micrograms / mL), mlpsi-mRNA-CFTR, but not circRNA-CFTR, caused cell death and abnormal automated conductance measurements, suggesting improved safety of circRNA relative to modified mRNA at higher doses.Example 5:Evaluation of the CF therapeutic efficacy of LNP-circRNA-CFTR in a CF mouse model 10131] To measure functional delivery of LNP-circRNA-CFTR in vivo, a bi-transgenic CFTR knockout (CFKO) mouse model was utilized in which the native mouse CFTR gene is fully knocked out and hCFTR is selectively expressed in the gastrointestinal tract to avoid intestinal complications. Following intratracheal administration of 0.1 mg / kg LNP-circRNA / mRNA-CFTR, lung tissues were collected for CFTR protein expression analysis.
[0132] To comprehensively evaluate the distribution and cellular targeting of LNP-circRNA-CFTR, was specifically investigated its delivery efficiency across different epithelial cell populations in the lung. Immunofluorescence analysis revealed CFTR expression in alveolar epithelial cells (HOP+), goblet cells (Mucin+). ciliated cells (Tubulin+), and club cells (SCGB1A1+), demonstrating broad transfection across key pulmonary epithelial subtypes (Fig. 5A, Fig. 5B, Fig. 5C and Fig. 5D). Notably, the restoration of CFTR in ciliated cells was particularly significant, as these cells play a pivotal role in mucociliary clearance and airway homeostasis, processes that are severely impaired in cystic fibrosis. Furthermore, these findings indicated that LNP-circRNA-CFTR delivery efficiently overcomes the limitations of conventional mRNA-based approaches by enhancing stability' and prolonging CFTR expression. The high transfection efficiency and sustained CFTR restoration in affected airway regions provide compelling evidence that circRNA-based therapeutics serves as a viable gene therapy strategy for cystic fibrosis.
[0133] Collectively, these findings demonstrate that LNP-circRNA-CFTR achieves efficient in vivo delivery and functional protein expression, surpassing mRNA in both efficacy and duration. The resulting CFTR protein not only restores chloride channel activity' but alsoDocket No. UM-44842.601improves lung function and structural integrity, highlighting its use as a therapeutic approach for CF.Example 6Evaluation of lung ventilation function by 4D-CT imaging in CF mice
[0134] Cftr-S489X CF mice were treated with circRNA-CFTR-psLNPs (10 pg RNA) and controls via intratracheal instillation once weekly for 4 weeks. On day 30, mouse lung function was evaluated using four-dimensional computed tomography (4D-CT) ventilation imaging (X-ray velocimetry) (FIG. 6 A), a clinically relevant readout analogous to forced expiratory volume at one second (FEV1) in CF patients. The study timeline is shown in FIG. 6B. 4D-CT captures gas distribution across the respiratory cycle without exogenous contrast, enabling calculation of voxel-wise specific ventilation, ventilation defect percentage (VDP), and ventilation heterogeneity' (VH). Compared with wild-type mice, untreated CF mice exhibited significantly increased VDP, elevated ventilation heterogeneity', and a higher proportion of low-ventilation regions (FIG. 6C). Treatment with circRNA-CFTR-psLNPs markedly improved these ventilation parameters, restoring VDP, ventilation heterogeneity, and low-ventilation region percentage to levels close to those observed in wild-type mice. circRNA-CFTR-psLNPs outperformed both circRNA-CFTR-LNPs and mRNA-CFTR-psLNPs formulations across multiple ventilation metrics. Representative coronal XV ventilation maps across respiratory phases confirmed that circRNA-CFTR-psLNPs visibly improved ventilation uniformity, whereas circRNA-CFTR-LNPs and mRNA-CFTR-psLNPs showed partial improvement (FIG.6D).Example 7Intranasal delivery of circRNA-CFTR-psLNPs restores CFTR function in CF rabbits
[0135] Using a nasal potential difference (NPD) assay, intranasally instilled circRNA-CFTR-psLNPs were evaluated for the ability to restore CFTR function in the nasal epithelia of F508del CF rabbits generated by CRISPR / Cas9 gene knock-in. Wild-type rabbits and ETI (elexacaftor-tezacaftor-ivacaftor)-treated F508del rabbits were used as controls. circRNA-CFTR-psLNPs and vehicle controls (30 pg RNA in 0.3 mL saline per nostril) were instilled onto the medial wall of one nasal cavity using syringes slowly over a period of 10 seconds, followed by administration into the other nostril. Over 9 days post-administration (dpa), animals w ere subj ect to NPD assay to evaluate CFTR function. The impaired response to CFTR agonist Forskolin in F508del rabbits was markedly corrected starting from 2 dpa, increased and plateaued at 5 dpa to a level comparable to those observed in wild-type rabbits or F508del rabbits treated with benchmark ETI therapy, and eventually returned to baseline by 9 dpa (FIG.Docket No. UM-44842.6017 A). A similar temporal patern was observed for the response to CFTR inhibitor-172 (FIG.7B). These findings show that single-dose circRNA-CFTR-psLNPs achieved therapeutically sufficient and sustained restoration of CFTR function in vivo, with efficacy lasting for up to 7 days.Example 8psLNP delivery to CF ferret airway epithelial cells
[0136] To assess psLNPs for RNA delivery across species, psLNPs loaded with mRNA encoding Cre recombinase (mRNA-Cre) were tested in fully differentiated ferret bronchial epithelia generated from Cre / Loxp reporter ROSA-TG ferrets. mRNA-Cre-psLNPs enabled abundant Cre-mediated conversion of GFP-positive cells, demonstrating efficient psLNP delivery of mRNA to ferret bronchial epithelia (FIG. 8A). Immunolocalization of GFP and epithelial cell subtype biomarkers revealed that psLNP-delivered mRNA-Cre was expressed in major epithelial cell subsets, including Forkhead Box JI (FOXJl)-positive ciliated cells and TP63-positive basal progenitor cells (FIG. 8B).Example 9Cell-type specificity and safety of circRNA-CFTR-psLNPs
[0137] To investigate cell-type specificity of pulmonary psLNP delivery, Ail4 Cre-reporter mice were administered mRNA-Cre-psLNPs (10 pg RNA) by intratracheal instillation. Three days later, lung tissue was harvested for tissue clearing and super-resolution 3D imaging, and for single-cell flow cytometric analysis. psLNPs showed efficient mRNA delivery to tracheal and lung epithelial cells (FIG. 9A). Flow cytometric analysis revealed that, relative to uncoated LNPs, psLNPs achieved up to 5.6-fold increased RNA delivery to up to 12.3% of EpCAM-positive lung and tracheal epithelial cells, as well as SiglecF-positive / CDl Ib-positive alveolar macrophages and CD1 Ic-positive dendritic cells, but not neutrophils or B / T cells (FIG. 9B). To assess safety, FVB mice were administered circRNA-CFTR-psLNPs by intratracheal instillation. Body weights were comparable across treatment groups. BALF cytokine ELISA showed that i.t. circRNA-psLNPs elicited only transient elevation of reactogenicity-associated interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) levels, resolved within 24 hours. H&E staining found minimal tissue-level side effects.Example 10CFTR expression in CF-relevant airway epithelial cells of Cftr-S489X CF mice
[0138] To assess circRNA-CFTR-psLNPs for CFTR expression in vivo, a CF mouse model carrying a Cftr-S489X null mutation was used. CFTR expression in the lung was analyzed 7 days after intratracheal instillation of 10 pg circRNA-CFTR or mlpsi-mRNA-CFTR loaded inDocket No. UM-44842.601psLNPs or control LNPs. Western blot of bulk lung homogenate showed that circRNA-CFTR-psLNPs restored high CFTR expression levels for at least 7 days (FIG. 10A. 10B). Immunofluorescence analysis revealed that, relative to controls, psLNPs enabled efficient CFTR expression in Mucin5 AC -positive goblet epithelial cells, Tubulin-positive ciliated cells, and SCGBlAl-positive club cells, indicating efficient circRNA delivery7and prolonged CFTR expression in CF-relevant airway epithelial cells for up to 7 days (FIG. IOC).Example 11Mucus penetration and pulmonary surfactant interaction by psLNPs
[0139] To understand the mechanism for efficient pulmonary7RNA delivery7by psLNPs, the interaction of psLNPs with airway mucus and pulmonary surfactant was studied using quartz crystal microbalance with dissipation (QCM-D). Ex vivo models of mucus and pulmonary surfactant were prepared under human CF airway-mimi eking buffer conditions (pH 5.6, ionic strength 154 mM). QCM-D monitored the quartz crystal resonance frequency7(F) and dissipation (D) over the course of adding, incubating, and rinsing LNPs versus psLNPs onto the models of mucus (FIG. 11A-C) or pulmonary surfactant, respectively, on gold substrates. Relative to LNPs, psLNPs enhanced the interaction with both mucus and pulmonary surfactant under CF physiological buffer conditions. These results indicate that psLNPs prolong retention in the airway, facilitate mucus penetration, and promote RNA delivery' to the underlying airway epithelial cells where CFTR function needs to be restored for CF therapy.
[0140] To assess psLNPs for mucus penetration in a CF airway epithelial mucus model, mucusproducing differentiated 16HBE-ge-G551D cells were cultured at air-liquid interface (ALI) in PneumaCult medium for 21 days to generate mucus (FIG. 12A). This ALI model of mucusproducing HBE cells closely mimics human CF airway conditions and native human sputum, including IL-13-tunable mucus secretion. psLNPs or LNPs loaded with Cy5-labeled circRNA or mRNA-EGFP were apically applied to the resulting mucus. Confocal fluorescence microscopy Z-stack imaging of Cy5 fluorescence signal intensity7across a 300-micrometer cross-section in the mucus-cell interface at 0.5 and 2 hours after treatment revealed that, relative to LNPs, psLNPs facilitated mucus penetration and RNA delivery7to the underlying HBE cells (FIG. 12B-C). In a parallel experiment, flow cytometric analysis of EGFP signal in ALI-cultured CF 16HBE-ge-G551D cells showed that psLNPs achieved approximately 25% EGFP -positive cells, compared to only approximately 15% for uncoated LNPs (FIG. 12D).Example 12Protein corona remodeling and antioxidant function of psLNPsDocket No. UM-44842.601
[0141] To assess the impact of PS coating on protein corona formation, Cy5-labeled circRNA-CFTR LNPs and psLNPs were incubated with bronchoalveolar lavage fluid (BALF), followed by size exclusion chromatography (SEC) purification to isolate nanoparticle-associated proteins for LC-MS / MS proteomic analysis. SEC profiles confirmed effective separation of nanoparticle-bound proteins from free proteins, enabling downstream proteomic characterization. Comparative analysis revealed that psLNPs exhibited a distinct protein corona composition relative to unmodified LNPs. psLNPs showed increased association with proteins involved in redox regulation and cellular metabolism, including antioxidant and metabolic regulators Akr7a2, Pgd, Ndufall, and Ndufs8, whereas stress-associated proteins such as Scampi and H2afz were relatively depleted (FIG. 13 A).
[0142] To determine whether these compositional changes translate into functional differences, oxidative stress induced by protein corona-coated psLNPs was evaluated. LNPs were first incubated with BALF to allow corona formation, followed by purification and treatment of MH-S alveolar macrophage cells. Tert-buty l hy droperoxide (tBHP) induced robust oxidative stress in MH-S cells (approximately 61.6% oxidative stress-positive cells), which was attenuated by the antioxidant N-acetylcysteine (NAC) (approximately 18.6%). Protein corona-coated LNPs induced oxidative stress of approximately 39.0%, whereas protein corona-coated psLNPs significantly reduced oxidative stress to approximately 19.0%, approaching levels observed with NAC treatment (FIG. 13B).
[0143] To validate these findings in vivo, LNPs or psLNPs were administered intratracheally to C57BL / 6 mice, followed by isolation of single cells from the lung for oxidative stress analysis. Consistent with in vitro results, LNP treatment markedly increased oxidative stress in epithelial cells (approximately 46.8%), whereas psLNPs significantly reduced oxidative stress to approximately 27.4%. approaching baseline levels (FIG. 13C). The enrichment of antioxidant-associated proteins in the psLNP protein corona, such as Akr7a2 and Pgd, which are involved in detoxification and NADPH-dependent redox pathways, suggests that psLNPs may provide a protective interface that mitigates oxidative stress in the CF lung environment. This may enhance the stability and translational efficiency of delivered circRNA-CFTR.Example 13CircRNA-CFTR biostability and thermostability
[0144] To study RNA thermostability, circRNA-CFTR and ml'P-mRNA-CFTR were stored in cryopreservant sucrose-supplemented PBS at -20°C for up to 7 days. Agarose gel electrophoresis and Imaged densitometric quantification showed the superior thermostability of circRNA-CFTR relative to ml'P-mRNA-CFTR, with circRNA-CFTR retainingDocket No. UM-44842.601substantially more intact RNA at all time points (FIG. 14A-B). Similarly, circRNA-CFTR showed superior biostability after incubation in diluted fetal bovine serum (FBS) at 37°C for 30 minutes (FIG. 14C-D). These results demonstrate that modification-free circRNA has higher stability than nucleotide-modified mRNA, which is important for long shelf-life, minimally stringent conditions for storage and transportation, and prolonged CFTR translation.REFERENCES
[0145] All publications, patent applications, patents, and other references mentioned in the specification are indicative of the level of those skilled in the art to which the presently disclosed subject matter pertains. All publications, patent applications, patents, and other references are herein incorporated by reference to the same extent as if each individual publication, patent application, patent, and other reference was specifically and individually indicated to be incorporated by reference. It will be understood that, although a number of patent applications, patents, and other references are referred to herein, such reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art. In case of a conflict between the specification and any of the incorporated references, the specification (including any amendments thereof, which may be based on an incorporated reference), shall control. Standard art-accepted meanings of terms are used herein unless indicated otherwise. Standard abbreviations for various terms are used herein.1. Jia S, Taylor-Cousar JL: Cystic Fibrosis Modulator Therapies. Amu Rev Med 2023, 74:413-426.2. Endres TM, Konstan MW: What Is Cystic Fibrosis? Jama 2022, 327(2): 191.3. Reis FJ, Damaceno N: [Cystic fibrosis], J Pediatr (Rio J) 1998, 74 Suppl ES76-94.4. Stutts MJ, Canessa CM, Olsen JC, Hamrick M, Cohn JA, Rossier BC, Boucher RC:CFTR as a cAMP-dependent regulator of sodium channels. Science 1995, 269(5225): 847-850.5. Guggino WB, Banks-Schlegel SP: Macromolecular interactions and ion transport in cystic fibrosis. Am J Respir Crit Care Med 2004, 170(7):815-820.6. Johnson LG, Boyles SE, Wilson J, Boucher RC: Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airw ay epithelial cells. J Clin Invest 1995, 95(3): 1377-1382.Docket No. UM-44842.601Rafeeq MM, Murad HAS: Cystic fibrosis: current therapeutic targets and future approaches. J Transl Med 2017, 15(1):84.Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH etal; Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010, 363(21): 1991-2003.Liu F, Zhang Z, Csanady L, Gadsby DC, Chen J: Molecular Structure of the Human CFTR Ion Channel. Ce / / 2017, 169(l):85-95.e88.Robinson E, MacDonald KD, Slaughter K, McKinney M, Patel S, Sun C, Sahay G: Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis. Mol Ther 2018, 26(8):2034-2046.Rowe SM, Zuckerman JB, Dorgan D, Lascano J, McCoy K, Jain M, Schechter MS, Lommatzsch S, Indihar V, Lechtzin N et al'. Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1 / 2 clinical study. J Cyst Fibros 2023, 22(4): 656-664.Abhyankar MM, Orr MT, Kinsey R, Sivananthan S, Nafziger AJ, Oakland DN, Young MK, Fan L, Uddin MJ, Leslie JL et al'. Optimizing a Multi-Component Intranasal Entamoeba Histolytica Vaccine Formulation Using a Design of Experiments Strategy. Front Immunol 2021, 12:683157.Qu L, Yi Z, Shen Y, Lin L, Chen F, Xu Y, Wu Z, Tang H. Zhang X, Tian F et al; Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 2022, 185(10):1728-1744 el716.Kariko K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D: Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability . Mol Ther 2008, 16(11): 1833-1840.Kim J, Eygeris Y, Gupta M, Sahay G: Self-assembled mRNA vaccines. Adv Drug Deliv Ztev 2021, 170:83-112.Gholamalipour Y, Johnson WC, Martin CT: Efficient inhibition of RNA self-primed extension by addition of competing 3'-capture DNA-improved RNA synthesis by T7 RNA polymerase. Nucleic Acids Res 2019, 47(19):ell8.Bloom K, van den Berg F, Arbuthnot P: Self-amplifying RNA vaccines for infectious diseases. Gene Ther 2021, 28(3-4): 117-129.Docket No. UM-44842.601Deering RP, Kommareddy S, Ulmer JB, Brito LA, Geall AJ: Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin Drug Deliv 2014, 11 (6): 885-899.Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC, Wicke L, Perkovic M, Beissert T, Haas H et al Self- Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses. Mol Ther 2018, 26(2):446-455.Jang SK: Internal initiation: IRES elements of picomaviruses and hepatitis c virus. Virus Res 2006, 119(1): 2-15.Komar AA, Hatzoglou M: Cellular IRES-mediated translation: the war of ITAFs in pathophysiological states. Cell Cycle 2011, 10(2): 229-240.Attal J, Theron MC, Houdebine LM: The optimal use of IRES (internal ribosome entry site) in expression vectors. Genet Anal 1999, 15(3-5): 161-165.Filbin ME, Ki eft JS: Toward a structural understanding of IRES RNA function. Curr Opin Struct Biol 2009, 19(3):267-276.Martinez-Salas E, Lopez de Quinto S, Ramos R, Femandez-Miragall O: IRES elements: features of the RNA structure contributing to their activity. Biochimie 2002, 84(8):755-763.Chen R, Wang SK, Belk JA, Amaya L, Li Z, Cardenas A, Abe BT, Chen CK, Wender PA. Chang HY: Engineering circular RNA for enhanced protein production. Nat Biotechnol 2023, 41(2): 262-272.Nielsen AF, Bindereif A, Bozzoni I, Hanan M, Hansen TB, Irimia M, Kadener S, Kristensen LS, Legnini I, Morlando M et al: Best practice standards for circular RNA research. Nat Methods 2022, 19(10): 1208-1220.Wesselhoeft RA, Kowalski PS, Anderson DG: Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun 2018, 9(1):2629.Wesselhoeft RA, Kowalski PS, Parker-Hale FC, Huang Y, Bisaria N, Anderson DG: RNA Circularization Diminishes Immunogenicity and Can Extend Translation Duration In Vivo. Mol Cell 2019, 74(3):508-520.e504.Holdt LM, Kohlmaier A, Teupser D: Circular RNAs as Therapeutic Agents and Targets. Front Physiol 2018, 9:1262.Obi P, Chen YG: The design and synthesis of circular RNAs. Methods 2021, 196:85-103.Docket No. UM-44842.601Qu L, Yi Z, Shen Y, Lin L, Chen F, Xu Y, Wu Z, Tang H, Zhang X, Tian F et al'. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 2022, 185(10):1728-1744.el716.Li H, Peng K, Yang K, Ma W, Qi S, Yu X, He J, Lin X, Yu G: Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies. Theranostics 2022, 12(14):6422-6436.Hou X. Zaks T, Langer R. Dong Y: Lipid nanoparticles for mRNA delivery. Nat Rev Mater 2021, 6(12): 1078-1094.Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M et al RNAi-mediated gene silencing in non-human primates. Nature 2006. 441(7089): 111-114.Jayaraman M, Ansell SM, Mui BL, Tam YK, Chen J, Du X, Butler D, Eltepu L, Matsuda S, Narayanannair JK et al'. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl 2012, 51(34):8529-8533.Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DW, Stebbing D, Crosley EJ, Yaworski E et al'. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010, 28(2): 172-176.Li B, Manan RS, Liang SQ, Gordon A, Jiang A, Varley A, Gao G, Langer R, Xue W, Anderson D: Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing. Nat Biotechnol 2023, 41(10): 1410-1415.Suk JS, Lai SK, Wang YY, Ensign LM, Zeitlin PL, Boyle MP, Hanes J: The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 2009, 30(13):2591-2597.Ensign LM, Schneider C, Suk JS, Cone R, Hanes J: Mucus penetrating nanoparticles: biophysical tool and method of drug and gene deliver}'. Adv Mater 2012, 24(28):3887-3894.Maeshima R, Tagalakis AD, Gyftaki-Venieri D, Jones SA, Rye PD, Tondervik A, Astrand OAH. Hart SL: Low Molecular Weight Alginate Oligosaccharides as Alternatives to PEG for Enhancement of the Diffusion of Cationic Nanoparticles Through Cystic Fibrosis Mucus. Adv Healthc Mater 2025, 14(l):e2400510.Griese M, Essl R, Schmidt R, Rietschel E, Ratjen F, Ballmann M, Paul K: Pulmonary surfactant, lung function, and endobronchial inflammation in cystic fibrosis. Am J Respir Crit Care Med 2004, 170(9): 1000- 1005.Docket No. UM-44842.601Kolonko AK, Efing J, Gonzalez-Espinosa Y, Bangel-Ruland N, van Driessche W, Goycoolea FM, Weber WM: Capsaicin-Loaded Chitosan Nanocapsules for wtCFTR-mRNA Delivery to a Cystic Fibrosis Cell Line. Biomedicines 2020, 8(9).Al-Nemrawi NK, Alshraiedeh NH, Zayed AL, Altaani BM: Low Molecular Weight Chitosan-Coated PLGA Nanoparticles for Pulmonary7Delivery' of Tobramycin for Cystic Fibrosis. Pharmaceuticals (Basel) 2018, 11(1).Hourihane E, Hixon KR: Nanoparticles as Drug Delivery Vehicles for People with Cystic Fibrosis. Biomimetics (Basel) 2024, 9(9).Fischer R, Schwarz C, Weiser R, Mahenthiralingam E, Smerud K, Meland N, Flaten H, Rye PD: Evaluating the alginate oligosaccharide (OligoG) as a therapy for Burkholderia cepacia complex cystic fibrosis lung infection. J Cyst Fibros 2022, 21(5):821-829.Chu CS, Trapnell BC, Curristin S, Cutting GR, Cry stal RG: Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet 1993, 3(2): 151-156.Ramalho AS, Beck S, Meyer M, Penque D, Cutting GR, Amaral MD: Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity7of pulmonary7disease in cystic fibrosis. Am J Respir Cell Mol Biol 2002, 27(5):619-627.Paunovska K, Sago CD, Monaco CM, Hudson WH, Castro MG, Rudoltz TG, Kalathoor S, Vanover DA, Santangelo PJ, Ahmed R et al'. A Direct Comparison of in Vitro and in Vivo Nucleic Acid Delivery Mediated by Hundreds of Nanoparticles Reveals a Weak Correlation. Nano Lett 2018, 18(3):2148-2157.Alton E, Armstrong DK, Ashby D, Bayfield KJ, Bilton D, Bloomfield EV. Boyd AC, Brand J, Buchan R, Calcedo R et al'. Efficacy and Mechanism Evaluation. In: A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis. Southampton (UK): NIHR Journals Library7, National Institute for Health Research. Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO167NS, UK.; 2016.Alton E, Armstrong DK, Ashby D, Bayfield KJ, Bilton D, Bloomfield EV, Boyd AC, Brand J, Buchan R, Calcedo R et al'. Repeated nebulisation of non-viral CFTR geneDocket No. UM-44842.601therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 2015, 3(9):684-691.Wesselhoeft RA, Kowalski PS, Parker-Hale FC, Huang Y, Bisaria N, Anderson DG: RNA Circularization Diminishes Immunogenicity and Can Extend Translation Duration In Vivo. Mol Cell 2019, 74(3):508-520 e504.Carrasco MJ, Alishetty S, Alameh MG, Said H, Wright L, Paige M, Soliman O, Weissman D. Cleveland TEt, Grishaev A et al: Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Commun Biol 2021, 4(1):956.Illek B, Maurisse R, Wahler L, Kunzelmann K, Fischer H, Gruenert DC: Cl transport in complemented CF bronchial epithelial cells correlates with CFTR mRNA expression levels. Cell Physiol Biochem 2008, 22(l-4):57-68.Zhou L, Dey CR, Wert SE, DuVall MD, Frizzell RA, Whitsett JA: Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 1994, 266(5191): 1705-1708.Patel S, Ashwanikumar N, Robinson E, DuRoss A, Sun C, Murphy -Benenato KE, Mihai C, Almarsson O, Sahay G: Boosting Intracellular Delivery of Lipid Nanoparticle-Encapsulated mRNA. Nano Lett 2017, 17(9):5711-5718.Grubb BR: Ion transport across the jejunum in normal and cystic fibrosis mice. Am J Physiol 1995, 268(3 Pt l):G505-513.Grubb BR, Boucher RC: Pathophysiology of gene-targeted mouse models for cystic fibrosis. Physiol Rev 1999, 79(1 Suppl):S193-214.Grubb BR, Vick RN, Boucher RC: Hyperabsorption of Na+ and raised Ca(2+)-mediated Cl- secretion in nasal epithelia of CF mice. Am J Physiol 1994, 266(5 Pt 1):C1478-1483.Xu J, Livraghi-Butrico A, Hou X, Rajagopalan C, Zhang J, Song J, Jiang H, Wei HG, Wang H, Bouhamdan M et al Phenotypes of CF rabbits generated by CRISPR / Cas9-mediated disruption of the CFTR gene. JCI Insight 2021, 6(1).Cholon DM, Quinney NL, Fulcher ML, Esther CR, Jr., Das J, Dokholyan NV, Randell SH, Boucher RC, Gentzsch M: Potentiator ivacaftor abrogates pharmacological correction of AF508 CFTR in cystic fibrosis. Sci Transl Med 2014, 6(246): 246ra296. Grubb BR, Gabriel SE, Mengos A, Gentzsch M, Randell SH, Van Heeckeren AM, Knowles MR, Drumm ML, Riordan JR, Boucher RC: SERCA pump inhibitors do notDocket No. UM-44842.601correct biosynthetic arrest of deltaF508 CFTR in cystic fibrosis. Am J Re spir Cell Mol Biol 2006, 34(3):355-363.
Claims
Docket No. UM-44842.601CLAIMSWhat is claimed is:
1. A lipid nanoparticle comprising a circular RNA encoding a functional cystic fibrosis transmembrane conductance regulator (CFTR).
2. The lipid nanoparticle of claim 1, wherein the circular RNA encodes a wild-type CFTR or a functional fragment thereof.
3. The lipid nanoparticle of claim 1 or 2, wherein the CFTR consists of CFTR coding sequence.
4. The lipid nanoparticle of any of claims 1 -3, wherein the lipid nanoparticle comprises SMI 02.
5. The lipid nanoparticle of any claims 1-4, wherein the lipid nanoparticle comprises a pulmonary surfactant (PS) coating.
6. The lipid nanoparticle of claim 6, wherein the PS coating comprises about 10% to 30% (w / w) of the total surfactant content.
7. The lipid nanoparticle of claim 6 or 7, wherein the PS coating comprises about 20% (w / w) of the total surfactant content.
8. The lipid nanoparticle of any claims 1-7, wherein the circular RNA comprises an internal ribosome entry site (IRES).
9. The lipid nanoparticle of any claims 1-8, wherein the circular RNA comprises a Kozak Sequence.
10. The lipid nanoparticle of any claims 1-10. wherein the lipid nanoparticle size ranges from 50nm to 150 nm and comprises a poly dispersity index (PD1) from 0.05 to 0.3.
11. Use of a lipid nanoparticle of any claims 1-10.
12. Use of a lipid nanoparticle of any claims 1-10, for the treatment or prevention of a pulmonary disease.
13. The use of a lipid nanoparticle of claim 13. wherein the pulmonary disease is cystic fibrosis (CF).
14. A composition, kit or system comprising the lipid nanoparticle of any one of the previous claims.
15. A method comprising administering a composition of claims 1-10 to a subject.Docket No. UM-44842.60116. A method comprising: administering a lipid nanoparticle comprising an RNA encoding a functional CFTR to a lung of a subject under conditions such that signs or symptoms of cystic fibrosis disease are reduced.
17. A method comprising: administering a lipid nanoparticle comprising an RNA encoding a therapeutic agent to lung ciliated cells and ionocytes of a subject, wherein the LNP further comprises SMI 02 and optionally a pulmonary surfactant.
18. The method of any of claims 15-17, wherein the RNA is a circular RNA.
19. The method of any of claims 15-18, wherein the subject has or is at risk for a pulmonary disease.
20. The method of claim 19, wherein the pulmonary disease is CF.
21. The method of claim 17, further comprising administering a pulmonary delivery device.
22. The method of claim 21, wherein said pulmonary delivery device is a nebulizer, a dry powder inhaler, a metered-dose inhaler, a metered dose spray pump, a soft mist inhaler or a inhalation therapy device.
23. The method of claim 17, wherein said administering results in restoration of physiological function of CFTR to transport Cl- across cell membranes of bronchial epithelial cells.
24. A method of producing a lipid nanoparticle, comprising encapsulating a circular RNA encoding CFTR by microfluidic mixing to form a lipid nanoparticle suitable for delivery' to target cells.
